Chemoprevention of Colon Cancer: Current Status and Future Prospects by Gustin, David M. & Brenner, Dean E.
Cancer and Metastasis Reviews 21: 323–348, 2002.
© 2002 Kluwer Academic Publishers. Printed in the Netherlands.
Chemoprevention of colon cancer: Current status and future prospects
David M. Gustin1 and Dean E. Brenner2
1Division of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL;
2Department of Internal Medicine, Pharmacology and Family Practice, University of Michigan Medical School
and Ann Arbor Veterans’ Affairs Medical Center, Ann Arbor, MI, USA
Key words: chemoprevention, colorectal cancer, surrogate endpoint biomarkers, drug development
Abstract
Colorectal cancer is an important public health problem in the western world. Although some progress has been
made in the prevention and management of this disease, colon cancer still remains one of the most common types
of epithelial malignancies in both genders and is essentially incurable when it reaches the most advanced stages.
Given the substantial morbidity and mortality associated with colorectal malignancies and their treatment, cancer
prevention in its many forms emerges as a very attractive approach. Colorectal cancer chemoprevention refers
to the administration of natural or synthetic compounds to block, reverse, delay or prevent the development of
invasive large bowel neoplasms. The ultimate goal of implementing a chemopreventive intervention in the general,
or alternatively, in an at-risk population is to decrease the incidence rate of the specific cancer being targeted. This
article reviews the present status of colorectal cancer chemoprevention. Current insights into the molecular and
genetic models of human colorectal carcinogenesis, preclinical models for efficacy testing as well as into promising
biomarkers for colorectal chemoprevention are provided. The developmental status of many promising agents is also
discussed emphasizing the epidemiological evidence, preclinical information substantiating an anticarcinogenic
effect, their postulated mechanism of action and the status of human clinical development. Our perspective of the
future prospects in this scientific area is also provided and has been predicated primarily on the firm belief that the
proper integration of advances in the biology of colon carcinogenesis, experimental therapeutics and clinical trial
methodology will be critical for the success of this promising field.
I. Introduction
Colorectal cancer is an important public health problem
in the western world. Although some progress has been
made in the prevention and management of this disease,
colon cancer still remains one of the most common
types of epithelial malignancies in both genders and is
essentially incurable when it reaches the most advanced
stages [1]. Given the substantial morbidity and mortal-
ity associated with colorectal malignancies and their
treatment, cancer prevention in its many forms emerges
as a very attractive approach. Colorectal cancer may be
prevented at different levels. Primary prevention lever-
ages the knowledge and manipulation of risk factors
that may be central to the initiation or development
of the carcinogenic process in the large bowel epithe-
lium. Operationally, it is usually conceptualized as the
avoidance of hazardous environmental carcinogens [2].
Secondary prevention refers to the early identification
and intervention in the transformation process in indi-
vidual subjects prior to the actual transforming event
[3]. Despite the attractiveness of a primary preventive
approach, population based preventive approaches
pose substantial challenges. Environmental risk fac-
tors for colorectal cancer remain poorly defined. Even
if well understood, they may be so prevalent in the
environment that their avoidance may not be feasible.
As the carcinogenic process is likely the product of
gene-environmental interactions, the environment is
not the only variable of interest. Our current inability
to manipulate the genetics of cancer risk substantially
limits our ability to implement primary prevention
at its highest level. A promising clinical interventive
strategy is that of cancer chemoprevention [4].
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Chemoprevention refers to the administration of
natural or synthetic compounds to block, reverse, delay
or prevent the development of invasive neoplasms.
The ultimate goal of implementing a chemopreven-
tive intervention in the general or alternatively in an
at-risk population is to slow the onset of cancer or to
decrease the incidence rate of the specific cancer being
targeted [4].
Although chemoprevention is a relatively new clini-
cal field, a substantial number of risk-reduction studies
have been completed to date, with mixed results [5].
Most of these studies were conceptualized when epi-
demiological, preclinical (in vitro and chemical car-
cinogenesis), serum and tissue bank data existed only
in very preliminary form. The unexpected results seen
with two of the major micronutrient cancer preven-
tion studies, the ATBC and CARET trials, underscore
the importance of having a systematic process in
place for the rational selection of the most promising
agents to be tested in definitive risk-reduction clinical
trials [6,7]. This process should include small-scale
biomarker driven human clinical studies.
This article reviews the current status of colorec-
tal cancer chemoprevention. Current insights into the
molecular and genetic models of human colorectal
carcinogenesis, preclinical models for efficacy testing
as well as into promising biomarkers for colorectal
chemoprevention are provided. The developmental
status of many promising agents is also discussed
emphasizing the epidemiological evidence, preclinical
information substantiating an anticarcinogenic effect,
their postulated mechanism of action and the status of
human clinical development. Our perspective of the
future prospects in this scientific area is also provided
and has been predicated primarily on the firm belief
that the proper integration of advances in the biology
of colon carcinogenesis, experimental therapeutics
and clinical trial methodology will be critical for the
success of this promising field.
II. Molecular basis of colorectal cancer
chemoprevention
Molecular genetics and biology have enhanced our
understanding of the developmental processes that are
involved in the genesis of colorectal neoplasms includ-
ing ‘sporadic’ colorectal malignancies as well as those
associated with inherited colon cancer syndromes. The
opposite is also true in that the elucidation of hereditary
genetic error provides us with a unique opportunity
to improve our understanding of the carcinogenesis
process. By defining the germ-line mutations associ-
ated with early transformation, we learn many of the
events and pathways that are mutated, methylated,
over or underexpressed in the carcinogenesis process
in sporadic neoplasms. With a more detailed under-
standing of the molecular biological processes (both
genetic and epigenetic) that are involved in colorectal
cancer genesis, molecular genetic models of human
carcinogenesis have emerged which provide a scien-
tific framework that serves as the platform for further
scientific inquiry in the field of chemoprevention.
Fearon and Vogelstein proposed a genetic model
where colon cancer was depicted as a process that
developed through the acquisition of a number of suc-
cessive genetic changes in an orderly fashion. A num-
ber of histopathological changes would then occur in
the colorectal epithelium as a phenotypic expression of
these genetic abnormalities [8]. Once mechanistically
understood, some of these events may become legiti-
mate and feasible targets in the search for new chemo-
preventive agents. In addition, they may serve as useful
markers of efficacy (surrogate endpoint biomarkers
(SEB)) or of risk for selection of suitable human cohorts
for clinical testing (high-risk populations). Fearon and
Vogelstein’s model is predicated on the notion that col-
orectal tumors occur as a consequence of mutational
activation of oncogenes paired with mutational inac-
tivation of tumor-suppressor genes. These mutations
occur in the background of evolving chromosomal
instability. Multiple mutations are to be required for
the development of malignant tumors whereas fewer
changes were necessary for premalignant lesions
(adenomas) to occur. They also postulated that the total
accumulation of changes was probably more important
than the sequence in which they occurred [8].
A number of key biochemical events associated with
colorectal carcinogenesis are presented here. This is
not meant to be an exhaustive list, but a brief summary
of the pivotal cellular changes associated with colorec-
tal carcinogenesis known to date. These events might
be overlapping, associated with different mutations or
methylation sites.
Adenomatous polyposis coli silencing. In the process
of sporadic colon carcinogenesis, the adenomatous
polyposis coli (APC) gene must be silenced [9]. APC
mutations occur in over 60–80% of adenomas and
sporadic carcinomas, and have been identified as the
germline genetic abnormality underlying the develop-
ment of familial adenomatous polyposis [10,11]. In the
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remaining 20–40% of sporadic colon cancers, the APC
gene is silenced by methylations of promoter sequences
[12,13]. The APC gene encodes for a 310 kDa protein
which phosphorylates cellular β-catenin. The phos-
phorylation reaction marks β-catenin to ubiquinitation.
Without this step, β-catenin accumulates in the cell
and transduces key cellular growth and proliferation
genes, including cyclin D and c-myc [14–17].
Cyclooxygenase-2 overexpression. The cyclooxyge-
nases (prostaglandin H synthase) (EC 1.14.99.1), are
two enzymes (Cox-1, Cox-2) that catalyze both oxida-
tive and reductive reactions in the prostaglandin syn-
thesis pathway [18–20]. Cox-1, a constitutive protein
contains a 17 amino acid sequence that is not present
in the inducible Cox-2 protein. Cox-2, an inducible
protein, contains an 18 amino acid sequence near its
carboxyl terminus that is not present in Cox-1. Cox-2
is induced by a wide range of mitogens, tumor pro-
motors and cytokines [21]. The Cox-2 5′ regulatory
sequence contains SP-1, NFκB, NF-IL6, AP-1, AP-2
sites, a serum response element, a cis-acting element
confirming responsiveness to gonadotropic hormones,
and an ATF/CRE site [21].
In normal human colon, Cox-1 is detectable by
Western blot in all human subjects assessed [22,23]
whereas Cox-2 appears to be variably present [22–
24] Cox-2 gene expression is increased in human
colon carcinomas when compared to normal mucosa
while not detecting upregulation of Cox-1 [25]. Cox-2
expression is enhanced in cancers. Cox-2 is detected in
cancer cells, inflammatory mononuclear cells, vascular
endothelial cells and fibroblasts. Poorly differenti-
ated tumors stain irregularly while well or moderately
differentiated tumors stain more diffusely [22].
It is reasonable to postulate that increased Cox-2
expression plays a major role in overexpression
of prostaglandins in malignant tissues from other
anatomic sites. Both viral (v-Src) and oncogene
(Ras) transformed mammary epithelial cells contain
increased Cox-2 mRNA and protein compared to
parental cells [26]. These data suggest that Cox-2
expression changes over the carcinogenesis process
with early high expression and then reduced expression
during or after transformation.
Genetic and phenotypic evidence suggests that
Cox-2 overexpression is related to neoplastic trans-
formation [27–29]. After transfection of a Cox-2
expression vector rat intestinal epithelial cells demon-
strate increased adherence to matrigel extracellular
matrix, blockade of apoptosis induced by butyrate,
increased bcl-2 expression, loss of E-cadherin protein,
and reduction of TGFβ2 receptors [30]. Apoptosis
is blocked by Cox-2 expression [13]. That Cox-2 is
expressed in noncolonic pretransformed and trans-
formed cells suggests a more global role for Cox-2 in
the carcinogenesis process.
Ras. Mutations of the ras oncogene have been well
documented in colorectal cancer patients at the early
and intermediate adenoma stages [8]. The farnesyla-
tion of Ras is critical for the appropriate localization
of this protein in the cell membrane, a step that is
essential for it to exert its function. A number of tar-
geted approaches are being developed in an attempt
to modulate the ras-signaling pathway. These include
natural agents such as d-limonene and perillyl alcohol
as well as targeted approaches to prevent the farnesyla-
tion of the Ras protein by the inhibition of the enzyme
farnesyl-transferase.
Deleted in colon cancer. Another frequent genetic
abnormality in colorectal cancer formation is the loss
of 18q21. This chromosomal abnormality is usually
seen at the later stages of adenoma formation. Two
putative tumor-suppressor genes have been mapped
to this region. Deleted in colorectal carcinogenesis
(DCC) gene deletions are present in over 70% of colon
carcinomas [31,32]. However, its function as a possi-
ble tumor-suppressor gene remains controversial.
Microsatellite instability. Late molecular events
include abnormalities of 17p associated with loss of
p53 function and other mutational events that result in
enhanced genomic instability associated with a replica-
tion error positive (RER+) phenotype. Microsatellite
instability (MSI) is the hallmark of hereditary nonpoly-
posis colorectal cancer syndrome (Lynch Syndrome).
Central to its pathogenesis is a colorectal epithelium
which is prone to errors in DNA repair due to muta-
tions of mismatch repair genes. Genes associated with
DNA repair include MSH2, MLH1, PMS2, PMS1 and
MSH6 [33–35]. These genetic mutations are germ-
line mutations and therefore are present early on in
subjects affected by the nonpolyposis colorectal can-
cer syndrome. Somatic mutations of the MLH1 and
MSH2 genes have been described in sporadic tumors
and in these cases seem to develop late in tumorige-
nesis [36]. Recently, mutations affecting the type II
TGF-β receptor (TGF-β RII) have been described in
sporadic, hereditary nonpolyposis colorectal cancer
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and ulcerative colitis-associated neoplasms. These
mutations may result in MSI and are discussed in more
detail in the following section [37,38].
Transforming growth factor beta II receptor mutations.
Tumor growth factor beta (TGF-β) is a family of ligands
that exert strong antiproliferative and pro-apoptotic
effects in nontransformed human colon epithelium
[39–43]. The TGF-β receptor is a heterodimeric recep-
tor complex conformed by two subunits, RI and RII
[40,44–50]. TGF-β signaling occurs through TGF-β
binding to its receptor complex which results in phos-
phorylation of Smad2 and Smad3, followed by their
association with Smad4, and subsequent translocation
of this complex into the nucleus, ultimately resulting in
the modulation of the expression of a number of genes
[45,49–51]. The end result of this process is growth
inhibition and promotion of programmed cell death.
A large proportion of human cancers display functional
resistance to TGF-β inhibitory effects. Approximately
one-third of this resistance occurs as a consequence of
mutations of the RII component of the TGF-β receptor.
In vitro studies suggest that RII functions as a tumor
suppressor. When wild type RII is reintroduced into an
RII mutant colon cancer cell line by infection with an
RII retrovirus, 90% of tumor colony formation is sup-
pressed [51].
A large proportion of RII mutations occur within
the RII coding region polyadenine repeat sequence
(BAT-RII) [52,53]. Human colon cancers with altered
base–base mismatch repair function, commonly dis-
play inactivation of RII tumor suppression function
through genetic changes affecting BAT-RII [52,53].
Fifteen percent of sporadic human colon cancers
display MSI as a consequence of loss of mismatch
repair function [54,55]. This seems to occur through
the silencing of mismatch repair genes via promoter
hypermethylation. An alternative pathway of human
colorectal carcinogenesis has therefore emerged in
which silencing of mismatch repair function, through
the hypermethylation of genes that participate in the
DNA base–base mismatch repair system (such as
hMLH1), promotes mutations in the BAT-RII segment
effectively targeting the RII tumor suppressor for inac-
tivation. These mutations seem to occur at the transition
stage between adenoma and carcinoma [56]. Func-
tional resistance to TGF-β has also been demonstrated
in colon cancers without TGF-β RII mutations. These
cases presumably have mutations on postreceptor ele-
ments of the TGF-β signaling pathway [56]. TGF-β
signaling is therefore a crucial pathway in human
colon carcinogenesis. Recent in vitro data suggests
that hMLH1 gene expression can be reconstituted after
treatment with the demethylating agent 5-azacytidine,
suggesting that these kinds of agents may have some
promise as colorectal chemopreventives [56].
III. Preclinical models of colorectal
carcinogenesis
The development of well-characterized preclinical
models of colorectal carcinogenesis has played a crit-
ical role in the process of screening and selection of
agents deserving further clinical study. Systems have
been developed to study the effects of putative chemo-
preventive agents on the modulation of relevant mecha-
nistic pathways associated with carcinogenesis (in vitro
systems) or to evaluate their overall effects in complex
organisms that try to emulate environmental carcino-
genesis (animal models of chemical carcinogenesis) or
genetic predisposition syndromes (genetically modi-
fied rodent models). In this review we will focus our
discussion on aberrant crypt foci (ACF) and on animal
models of carcinogenesis.
III.A. Aberrant crypt foci
The smallest recognizable histopathologic evidence
of colorectal epithelial carcinogenesis is the ACF or
microadenoma. ACFs are lesions consisting of large,
thick crypts seen in methylene-blue stained speci-
mens of colon, originally found in mice treated with
azoxymethane (AOM) [57]. In humans, two types
of ACF are observed after methylene blue stain-
ing of whole mount mucosa preparations: hyperplas-
tic foci (hypercellullar but normal appearing cells)
and dysplastic foci (contain dysplastic cells similar
to those found in adenomas) [58–60]. Hyperplastic
lesions commonly contain K-ras gene mutations, rarely
contain APC mutations [61–63], and are unlikely to
progress to neoplasia.
For several reasons, dysplastic lesions are thought
to be precursors to adenomas. Numerous dysplastic
ACFs are found in familial adenomatous polyposis
patients [64]. Moreover, the occurrence patterns of
ACF and their response to chemopreventive interven-
tions parallel those of adenomas and carcinomas in
rodent carcinogenesis models [57,65–67]. Dysplastic
human ACFs contain APC mutations, cellular hyper-
proliferation to the top of the crypt, and disruption
of p21/Ki67-hMSH2 crypt compartmentalization, all
features common to adenomas [59,61,63]. Finally,
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carcinoma in situ has been documented in human ACF
[64]. Takayama et al. [62] reported that the preva-
lence of dysplastic ACFs in the rectosigmoid was 5.1%,
13.8% and 52.1% in normal subjects, those with prior
adenomas, and those with prior carcinoma respectively.
Siu et al. [68] reported dysplasia in 48% of rectosig-
moid ACFs but do not describe the pathologic diag-
noses associated with their samples. The data to date
suggest that dysplastic ACFs may have a potential role
as early pathologic surrogate endpoints for colorectal
cellular transformation; however, the evidence is not
conclusive. Rather, ACFs represent an excellent early
pathologic surrogate to assess in rodent models and,
potentially, in humans.
III.B. Animal models of chemical carcinogenesis
Animal models represent a pivotal step in the effi-
cacy evaluation of chemopreventive agents. Chemical
carcinogenesis rodent models provide reproducible
development of tumors in the intestinal epithelium of
rodents that have been exposed to a chemical com-
pound which acts as an initiator or a combination of
two chemicals that act as initiator–promoter pairs.
These models have been most extensively used as
pre-clinical in vivo platforms for efficacy testing of
chemopreventive leads. Frequently used chemical car-
cinogens include dimethylhydrazine (DMH), AOM,
methoxymethane (MAM) and N-methyl-N-nitro-N-
nitrosoguanidine (MNNG) [69,70]. Most of these com-
pounds act through methylation of DNA nucleosides
(primarily guanine) which eventually results in critical
DNA mutations [71]. Dimethylhydrazine undergoes
conversion to AOM and azoxymethanol which are
subsequently conjugated with glucuronic acid and
excreted in the bile. Bacterial hydrolysis occurs once
the conjugated carcinogens reach the intestinal lumen
but is not essential to their tumorigenic effect. A num-
ber of variables such as the dose, route and timing of
carcinogen administration, the species of rodent being
used and the age of the animal at the time of injec-
tion can be manipulated to provide the investigator
with some control over critical features in the model.
These features that can to some extent be controlled
include latency period, development (or lack thereof)
of extracolonic tumors (large bowel specificity) and
tumor distribution [72–74]. Molecular characteriza-
tion of some of these models is presently an area of
active inquiry. AOM induces changes in the rodent
intestinal mucosa that closely replicate, histologically,
the adenoma-carcinoma sequence in humans [75].
Chemical carcinogens are also capable of inducing
some of the molecular changes that are commonly seen
during human carcinogenesis. APC mutations have
been described in experimental colorectal carcinogen-
esis induced by AOM in F344 rats, but seem to occur
less frequently in this model than in humans [76,77].
A substantial body of literature supports the presence
of K-ras mutations in the AOM model [78–81]. Muta-
tions of p-53, however, do not seem to be involved in the
development of colon cancer induced by AOM in the
rat [82,83]. Other pathways which seem to play impor-
tant roles during both human and rat colon (chemical)
carcinogenesis include the constitutive activation of the
Wnt-signaling pathway, altered expression of cyclin
D1 and cyclin-dependent kinase 4 (Cdk4) and others
[84,85]. MSI has also been described in AOM-induced
rodent cancers although seems to occur with much less
frequency than in humans [86]. Chemically-induced
carcinogenesis in rodents and human carcinogenesis
are not identical. However, since AOM-induced rat
colonic neoplasms are similar to human colonic tumors
in their histological features and proliferation char-
acteristics, and given some of the molecular parallels
that exist between rodent and human carcinogenesis,
these models are usually regarded as relevant tools for
preclinical in vivo testing of new chemopreventives.
III.C. Genetic models
Single and multiple gene knock out and genetic
mutational rodent models provide new and important
insights into the carcinogenesis process of colonic
epithelium. A mouse pedigree derived from treatment
with N-ethyl-N-nitrosurea (ENU) causes a mutated
APC resulting in a truncated protein similar to those
found in humans (Min+) [87]. The mutated gene dis-
plays full penetrance and is dominantly expressed [88].
Genes that act as modifiers of tumor number have also
been demonstrated and designated as Modifiers of Min
or ‘Mom’ genes [89]. Min+ mice are increasingly being
used as chemopreventive agent screening platforms.
For example, Cox-2 inhibitors reduce but do not totally
eliminate adenomas in these mice [90,91].
While highly attractive experimental and mecha-
nistic models, genetically induced mutations in APC
have not created an animal that is realistically close to
human carcinogenesis. Although these models develop
intestinal neoplasms with a histologic sequence simi-
lar to that observed in intestinal tumors of humans, the
latency time for the development of these neoplasms
if very short compared to human lifespans. Moreover,
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the neoplasms occur primarily in the small intestine
not in the colon and are submucosal, not polypoid.
Adenomas and carcinomas in the Min+mice do not
display common mutational events found in human
tumors such as ras and p53 mutations [92]. These find-
ings suggest that APC mutations may be a common
early event in human and genetically-modified rodent
carcinogenesis; but subsequent mutational events play
equally important roles in the phenotypic expression of
carcinogenesis in sporadic human tumors. These dif-
ferences require investigators to approach chemopre-
ventive efficacy data from genetically modified rodent
models with caution.
IV. Surrogate endpoint biomarkers for
colon cancer chemoprevention
Since the process of colorectal carcinogenesis can take
years to decades, assessment of clinical chemopreven-
tion trials using cancer incidence as an endpoint would
require extended follow-up periods and very large sam-
ple sizes. Given the large number of agents with chemo-
preventive potential currently under development, it is
not feasible to use cancer incidence reduction or large
polyp prevention clinical trials as a primary method of
assessing preventive agent efficacy in humans. A solu-
tion to this problem involves the design and implemen-
tation of short duration, limited cohort human trials of
potential chemopreventive agents that use surrogate
markers of carcinogenesis, biological or morphologic
events, in lieu of the actual cancer [93].
An ideal biomarker would demonstrate variabil-
ity of expression across the different carcinogenic
stages, detectable early in the carcinogenesis process,
and linked to the occurrence of precancer or cancer.
A chemopreventive agent can modulate this ideal
biomarker and the degree of modulation reflects the
efficacy of the agent. The modulation of the precan-
cerous stage should result in predictable changes in
the ultimate endpoint of interest: cancer incidence.
Very few if any of the biomarkers currently avail-
able or in use meet all or most of these criteria
[94]. Many promising SEBs for colorectal cancer
chemoprevention are currently being evaluated [95]
(Table 1). A surrogate marker may be associated with
a specific phase of carcinogenesis and/or it may be
mechanistically linked to the mode of action of the
agent being evaluated. SEB currently under evaluation
include pathologic markers (adenomatous polyps),
functional cellular biomarkers (proliferation, apoptosis
and differentiation), biochemical markers (enzymatic
function and their metabolites), and molecular as well
as genetic markers.
Biomarkers must be validated prior to use in chemo-
prevention clinical trials. Validation procedures are
step wise and consist of the following:
Stage 1 – Preliminary clinical biomarker charac-
terization: In order to interpret future data and to
appropriately design subsequent validation trials, clin-
ical characterization of a biomarker is necessary:
within-day and between-day variability, variability
within subjects and among subjects as well as gender
differences.
Stage 2 – Cross sectional case-control screen with
model construction: This is a case-control sample.
Biomarkers are measured from subjects with and with-
out neoplasia. The data are analyzed in a linear model
for predictive efficacy. A logistic regression model may
be used to create a clinical prediction rule.
Stage 3 – Observational longitudinal study: This
study focuses on temporal associations and prediction
of future clinical events. The design follows up high-
risk people for a clinical endpoint using baseline bio-
marker measurement as well as serial measurements of
biomarkers over time. Changes in biomarkers are asso-
ciated with the clinical event. The data are analyzed
using linear models and predictive efficacy.
Stage 4 – Long-term randomized intervention: This
design collects data on a relevant clinical endpoint in
a more prolonged prospective randomized clinical trial
of a therapeutic intervention. Such a study addresses
the questions (a) Is the biomarker a surrogate endpoint?
(b) Can the biomarker be used to evaluate a specific
therapy? (c) To what extent can the effect of the treat-
ment be explained by the effect on the biomarker?
IV.A. Pathologic biomarkers
These group of biomarkers refer to histological lesions
that are amenable to modulation by a chemopreventive
agent. Adenomatous polyps have received substantial
attention as pathologic biomarkers of colorectal can-
cer. Results from the National Polyp Study suggest that
the majority of invasive colorectal adenocarcinomas
pass through the adenoma stage prior to transformation
and invasion. Adenoma resection is associated with a
70% decrease in the incidence of infiltrating colorec-
tal neoplasms [96]. Furthermore, the relatively high
recurrence rate of these lesions in a short period of time
after their removal (up to 50% in 2 years), makes them
useful and practical endpoints to be used in efficient and
short biomarker-driven clinical studies [97]. Given the
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Table 1. Possible biomarkers for use in early human colorectal chemoprevention studies
Class Biomarker















Polyunsaturated acid metabolism Prostaglandins (PGE2)
Cyclooxygenases (COX-1 and COX-2)
Lipooxygenases (5-, 8-, 12-, 15-LOX)
Polyamine metabolism Polyamines (spermine, spermidine, putrescine), ODC
Phase II enzymes Glutathione-S-transferase
Molecular Markers Cyclin D1
NFκB system (NFκB proteins, IκB proteins)
Genetic Markers Ras (gene and protein)
APC (gene and truncated protein)





National Polyp Study data, it is not surprising the many
observers consider prevention of adenoma recurrence
as sufficient evidence of chemopreventive efficacy to
permit drug labeling and marketing [98]. Such a posi-
tion remains controversial, with many believing that
invasive adenocarcinomas of the large bowel may occur
without a polypoid dysplastic stage. The recent interest
in flat adenomas with dysplasia supports the position
that flat dysplastic lesions commonly occur in the colon
[99–103]. The lesions may predict for more aggressive
behavior than standard polypoid lesions, are commonly
missed on routine endoscopies in North America, and
may represent a form of dysplasia in the colonic epithe-
lium without the classical polypoid adenoma.
IV.B. Biochemical biomarkers
These SEBs refer to biochemical events in the target
cell, which may be modulated by a chemopreven-
tive compound. Usually, they are closely related to
the mechanism of action of the agent under study.
A possible strategy for their initial evaluation may
involve looking at how well their modulation cor-
relates with favorable effects on a pathologic or on
a cellular marker. Good examples of these kinds of
biomarkers include the measurement of biochemical
events associated with COX activity, lipooxygenase
(LOX) activity and polyamine metabolism [104–107].
They may be useful as pharmacodynamic endpoints
in Phase I chemoprevention studies. In principle, dose
selection in early human chemoprevention studies
should not be guided only by safety considerations,
but also the lowest ‘bioefficacious’ dose should be
sought whenever possible because chemopreventive
interventions may be used for life in populations that
are for the most part healthy [108].
IV.C. Cellular markers
IV.C.1. Markers of proliferation and differentiation
A number of assays have been developed to mea-
sure cellular proliferation (e.g. labeling indices using
tritiated thymidine, bromodeoxyuridine [BrdU], pro-
liferation cell nuclear antigen [PCNA], Ki67) [95,109].
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Interventions that reduce proliferation have been con-
sidered to retard or halt the process of cancer gen-
esis. However, this assumption may not necessarily
be true. Cellular differentiation is evaluated through
the expression (or lack thereof) of markers that reflect
proper epithelial maturation. Propensity towards an
undifferentiated phenotype is characteristic of neoplas-
tic processes. Molecules that are expressed in a fully
differentiated epithelial cell may then be used as a
marker of the pro-differentiating effects of an interven-
tion. For example, Dilidros biflorus agglutinin (DBA)
which labels mucin in goblet cells has been used as a
marker of differentiation. Undifferentiated phenotypes
are associated with failure of oligosaccharide synthesis
and a decrease in DBA staining [110]. Reduced staining
has been documented in colon adenomas and cancers
as well as some familial colon cancer syndromes [111].
IV.C.2. Markers of apoptosis
Normal colonic epithelial homeostasis requires a
proper balance between cell proliferation and pro-
grammed cell death [112]. Failure of apoptotic func-
tion is characteristic of neoplastic phenotypes and may
play a role in tumor progression [113]. A number of
biochemical and genetic changes have been associated
with inhibition of apoptosis. An example relevant to
chemoprevention of colorectal malignancy involves
the association between COX-2 overexpression and
failure of apoptosis [114]. Furthermore, modulation of
COX-2 enzymatic activity may result in reconstitution
of apoptotic capability. Quantitation of apoptotic end-
points in colonic epithelium has been difficult. Many
investigators including ourselves have not been able
to detect fragmented DNA in situ characteristic of the
apoptotic endpoints as measured by TUNEL immuno-
histochemistry. TUNEL positive cells account for less
than 1% of all rat colonic epithelial cells in the normal
colonic crypt, a surprise finding considering that the
apoptotic program is activated as colonic crypt cells
senesce at the top of the crypt [115]. Other meth-
ods of detected apoptotic activity in human colonic
crypts (flow cytometry, caspase induction, Bcl-2/Bax
ratio) have not been sufficiently explored to be use-
ful as reproducible biomarkers of apoptosis in the
human colonic crypt. Apoptosis indices using TUNEL
have proven useful biomarkers in human adenoma-
tous polyps [116]. Apoptotic endpoints as biomarkers
for chemopreventive activity in morphologically nor-
mal human colonic epithelium, while of interest and
potential importance, remain unvalidated.
IV.D. Molecular markers
Critical components of signal transduction pathways
may theoretically be used as surrogate markers in
chemoprevention if linked in some form to epithelial
carcinogenesis [95]. Cell cycle regulators such as
cyclin D proteins are a good example. Rodent epithe-
lial cells engineered to overexpress COX-2 display
increased levels of cyclin D1 and delayed G1 progres-
sion. Cyclin D1 overexpression may increase the num-
ber of cells in S-phase. Treatment with nonsteroidal
antiinflammatory drugs (NSAIDs) may promote cell
cycle suppression through the modulation of COX-2
expression. Thus, cyclin D1 is a reasonable candidate
for further validation as a surrogate marker [117]. The
pathways associated with prostanoid metabolism and
signaling are probably the ones that have received the
most attention in colorectal cancer chemoprevention.
As our understanding of the relationship between the
metabolism of polyunsutared fatty acids and carcino-
genesis has improved, a number of new molecular
targets have emerged [118,119]. A good example
relates to prostaglandin E2 (PGE2) signaling. PGE2 has
been implicated in epithelial carcinogenesis. We now
know that there are at least four different membrane
prostanoid receptors that mediate PGE2 signaling:
EP1, EP2, EP3 and EP4 [119]. Knockout mice defi-
cient in each of these receptors have now been devel-
oped and are helping to improve our understanding of
downstream events to COX function that may more
specifically relate to cancer genesis. EP1-deficient
mice exposed to the carcinogen AOM demonstrated
increased resistance to the development of ACFs, an
early step in rodent colorectal carcinogenesis [120].
These protective effects suggest that signaling through
EP1 is critical to the permissive effects of PG on col-
orectal carcinogenesis. Molecules involved with EP1
signaling or EP1 itself may then become surrogate
markers of the anticarcinogenic effects of agents that
target prostanoid metabolism as well as more specific
targets for the development of novel chemopreventive
approaches. Furthermore, we now know that the protec-
tive effects of NSAIDs may not only relate to inhibition
of COX but to the modulation of LOX. LOX enzymes
metabolize arachidonic acid into diverse and multi-
functional metabolites. Some of these pathways seem
to be procarcinogenic (5-, 8- and 12-LOX) and others
seem to display protective effects against carcinogene-
sis (15-LOX-1 and 15-LOX-2). This new information
suggests that when LOX activity is being modulated
with a chemopreventive intent, close attention needs
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to be paid to the balance between procarcinogenic
and anticarcinogenic LOX effects [118]. Thus, as
signaling pathways involved with carcinogenesis are
better known and their critical molecular components
identified, our opportunity to develop novel, more
specific and better biomarkers will also increase.
IV.E. Genetic biomarkers
As our understanding of the genetic changes asso-
ciated with human colon tumorigenesis increases,
so does our opportunity to develop novel targeted
interventions. These therapeutic approaches would be
directed towards the modulation of critical genetically
determined molecular abnormalities. Assays can then
be established and validated to measure some of these
pathways, which may serve as surrogate markers of
therapeutic bioactivity. Furthermore, genetic abnor-
malities associated with the initiation or progression
of colorectal carcinogenesis involves the development
and expansion of premalignant clones that may be
defined and quantified through the detection of specific
mutations. The ability of chemoprevention agents of
inducing clearance of abnormal clones thus identified
can then be used a surrogate marker of bioactivity.
Using PCR-based methods, it is now possible to qual-
ify and quantify critical mutations not only in tissue
but also in exfoliated cells present in body fluids such
as urine, respiratory secretions and feces. These mea-
surements would have clinical value only if they cor-
relate with favorable changes in the actual epithelium
at risk. Preclinical in vivo data generated using rodent
models of chemical carcinogenesis suggest that these
approaches may have some promise. For instance,
difluoromethylornithine (DFMO) a chemopreventive
agent thought to work through the modulation of the
enzyme ornithine decarboxylase (ODC) can block
the expression of K-ras [121]. NSAIDs have been
shown to decrease the expression of p53 and K-ras
on preclinical models of carcinogenesis [122]. These
changes presumably occur through the elimination of
premalignant (or malignant) clones.
An increasing body of literature suggests that muta-
tions and other structural changes of DNA such as dele-
tions or amplifications offer only a partial view into the
events that modify gene expression. The methylation
of gene promoters has been shown to have a critical
impact on gene transduction. In fact, DNA methyla-
tion is now recognized as one of the most common
abnormalities in human neoplasms [123]. CpG din-
ucleotides have substantial biological properties and
are excellent substracts for DNA methyltransferase
[124]. Approximately 70% of cytosines (in CpG din-
ucleotides) present in human DNA undergo methyla-
tion. CpG islands (CPI) are formed by the enrichment
of segments of DNA with a large number of CpG
dinucleotides (0.5–2 kB long). CPIs are found in the
5′ region of a large number of genes [124]. Young
individuals display CPIs that are for the most part
unmethylated [124]. CpG islands in promoter regions
need to be in an unmethylated state in order to allow
the involved genes to remain in an actively transcribed
(or transcription-ready) state [125]. There is ample
evidence that support hypermethylation of CPIs as a
common mechanism causing inhibition of gene expres-
sion [126]. The mechanism by which hypermethyla-
tion impairs gene transcription is not totally clear. It
has been postulated that hypermethylation may inter-
fere with binding of transcription complexes to spe-
cific regulatory segments of DNA. This is possible as
many transcription factors have GC-rich binding sites
as well as CPIs in their DNA recognition elements
[127]. An alternative mechanism suggests that methy-
lation may induce changes in the nucleosome core that
result in interference with gene transcription. Histone
hyperacetylation plays an important facilitating role
in DNA transcription. Hypermethylation may induce
changes in the composition of DNA in terms of content
of hyperacetylated histones affecting gene transcrip-
tion and functionally inducing gene silencing [128].
Hypermethylation seems to play an important role in
the inactivation of a number of tumor suppressor genes
involved in colorectal carcinogenesis. Inactivation of
p16INK4a , hMLH1 and APC genes by hypermethylation
has been described in colonic cancers [129–131]. The
proportion of hypermethylation of the APC gene in pre-
malignant as well malignant lesions of the colon is the
same (approx. 18%) [131]. Ample experimental data
supporting hypermethylation as an important mecha-
nism of inactivation of other relevant tumor suppressor
genes in colorectal cancer has been reviewed elsewhere
[132]. Hypermethylation is a crucial component of car-
cinogenesis. This component may be therapeutically
targeted and exploited as biomarkers of carcinogenesis
progression [133].
V. Promising agents for colorectal cancer
chemoprevention
Here, we review some of the most promising dietary
and pharmacological compounds currently under
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evaluation for the chemoprevention of colorectal
malignancies (Table 2). This is not meant as a com-
prehensive evaluation of potential chemopreventive
agents. Rather, we have selected the more promising
agents and approaches for review.
V.A. Nonsteroidal antiinflammatory drugs
Epidemiology. In the majority of multiple population-
based case-controlled studies, aspirin has repeatedly
been found to confer a 50% reduction in risk of occur-
rence of colorectal cancer [134–137]. The largest study
consisted of 662,424 North American adults evaluated
over a 7-year period (1982–88). On multivariate analy-
ses, a significant relationship between the use of low
doses of aspirin and decreased risk of colorectal can-
cer was demonstrated [135,136]. While not all studies
have demonstrated a connection between aspirin intake
and colorectal cancer risk reduction [138], there is
strong evidence for an association between aspirin use
and colorectal risk reduction.
Animal models. Colonic tumorigenesis induced by
1,2-dimethylhydrazine (1,2-DMH) or its metabolites
methylazoxymethanol and AOM can be suppressed
by treatment of rats with NSAIDs, the most work has
been completed using indomethacin and piroxicam
[139–142], but many other NSAIDs including sulin-
dac, ibuprofen and ketoprofen have been shown to
be chemoprotective in both tumor endpoint and the
shorter term ACF assay studies [143,144]. Aspirin
at 40% and 80% of maximum tolerated dose admin-
istered in the diet of AOM treated male F-344 rats
caused significant suppression of colonic mucosal
PGE2 levels and was associated with inhibition in the
incidence and number of these tumors [145]. These
drugs act, at least in part, during the promotion phase
of carcinogenesis, in that most of the chemopreventive
activity is retained if piroxicam is started as late as
14 weeks after carcinogen administration [143]. Selec-
tive cyclooxygenase-2 inhibitors, are potent colonic
chemopreventive agents in rodent models [146,147].
The rodent model data provide a strong and consistent
body of information supporting the study of NSAIDs
as colorectal carcinoma chemopreventives.
Human studies. Many human studies using a vari-
ety of NSAIDs have been conducted to date. Patients
with familial adenomatous polyposis have been an
obvious at-risk group which has been targeted in
some of these studies. Three of these studies were
small, randomized clinical trials in which sulindac was
administered. Altogether, a total of 45 FAP patients
were treated on these studies, and the administration of
Table 2. Agents under study or with developmental potential for colorectal cancer chemoprevention
Class Sample Agents Proposed mechanism of action
Non-selective non-steroidal Aspirin, sulindac, piroxicam Inhibition of COX enzymes, suppression of prostaglandin
anti-inflammatories synthesis (PGE2), modulation of LOX,
non-COX-related mechanisms, pro-apoptotic mechanisms
Selective non-steroidal Celecoxib, rofecoxib Inhibition of prostanoid metabolism through the selective
antiinflammatories inhibition of COX-2
(COX-2 inhibitors)
Micronutrients Calcium and vitamin D Binding of bile and fatty acids, induction of cellular differentiation
Vitamin C Blocking agent (neutralization of carcinogens), antioxidant
Vitamin E Antioxidant
Organoseleniums (e.g. Inhibition of carcinogen activation, decrease in DNA binding of
P-methoxybenzyl selenocyanide) carcinogens, antioxidative properties, others
Monoterpenoids (e.g. Ras inhibition
d-limonene, perillyl alcohol)
Curcuminoids COX-inhibition, LOX-modulation, antioxidation,
anti-angiogenesis, modulation of NFκB
Folate DNA synthesis, DNA methylation
Polyamine inhibitors Difluoromethylornithine (DFMO) Affects the production of polyamine through the inhibition
of ornithine decarboxylase
Hormones Estrogens Decrease production of secondary bile acids, inhibition of
insulin-like growth factors
Complex dietary interventions Fiber (especially wheat bran) Carcinogen binding, bile-acid binding, promotion of stool bulk,
decrease conversion of primary into secondary bile acids
Berries (black raspberries) Multimechanism
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sulindac resulted in a statistically significant decrease
in the number of polyps [148–150]. A fourth placebo-
controlled randomized clinical study was reported by
Steinbach and coworkers, in which a COX-2 inhibitor
(celecoxib) was tested at two different dosing sched-
ules (100 mg twice daily and 400 mg twice daily). Sub-
jects were treated for a total of 6 months. Treatment
with the lower dose resulted in a decrease in the num-
ber of polyps by 12% from baseline and did not reach
statistical significance. Celecoxib at the highest dose
was able to reduce the number of polyps by 28% from
baseline. This reduction was statistically significant
(P = 0.003) [151]. Baron et al. have recently reported
that aspirin reduced sporadic adenoma recurrence at a
dose of 81 mg daily. This preliminary report remains
to be published at the time of this publication.
These provocative data suggest that NSAIDs are
likely to play some role in prevention of colorectal
cancer. However, at this time, the magnitude of the ben-
eficial effect and the risks of chronic intake of NSAIDs
over a long period of time do not seem sufficient to
endorse NSAIDs as a colorectal cancer chemopreven-
tive in individuals at risk for sporadic cancers. While
COX-2 inhibition has demonstrated chemopreventive
activity in human subjects with familial adenomatous
polyposis, the effect is modest and does not replace
frequent screening. Moreover, new cases of colorectal
cancer have been reported in FAP patients undergoing
chemopreventive treatment with NSAIDs [152]. The
beneficial effects of NSAIDs and COX-2 inhibitors on
polyp formation are transient and disappear soon after
drug withdrawal [153]. This suggests that chemopre-
ventive approaches that modulate COX may need to
be maintained for life in order to be efficacious in this
patient population.
V.B. Dietary multimechanistic compounds
Ample epidemiologic information supports the notion
that diets rich in fruits and vegetables are protective
against a variety of cancers, including colorectal neo-
plasms [154]. Based on this information, a number of
investigators have attempted to identify the specific
compounds in diet that concede protection. Interpreta-
tion of observational epidemiologic studies is difficult,
as micronutrients and other dietary components are
consumed in the form of more complex dietary ele-
ments (whole fruits or vegetables), which contain
a variety of other substances which could conceiv-
ably display chemopreventive properties. Nutritional
science has made some progress in the develop-
ment of improved tools for the estimation of specific
micronutrient ingestion, derived from complex dietary
information. These tools have allowed the study
of protective associations between specific dietary
components and cancer occurrence. Unfortunately,
substantial methodological problems still remain and
further refinements of these methods are still needed
[155]. The epidemiologic data derived from patterns of
dietary consumption, should be regarded as hypothesis
generating, and must be subjected to proper scrutiny
in well-designed preclinical and clinical experiments.
A large number of specific compounds have been iden-
tified through epidemiological techniques as possible
colorectal cancer chemopreventives. Many of these
compounds have been subjected to stringent preclin-
ical and clinical evalution, and some of them will be
presented in this review.
V.B.1. Calcium
Epidemiology. Epidemiological data regarding the
association between calcium ingestion and colorectal
cancer (or adenoma) risk have varied. A number of
case-control and cohort studies have suggested that
increase intake of calcium and of vitamin D may be
associated with a protective effect. However, other
studies have not clearly supported this association.
The Iowa Women’s Health Study investigated whether
a high intake of calcium, vitamin D or dairy products
protected against colon cancer. In this report, data
obtained from a prospective cohort study of 35,216
Iowa women over 55 years of age who had completed a
dietary questionnaire in 1986, was analyzed. The asso-
ciation between dietary calcium, vitamin D and the
incidence of colorectal cancer was studied. The relative
risks (RR) observed for the highest quintile of intake as
compared with the lowest were 0.52 (95% confidence
interval (CI) 0.33–0.82) for calcium and 0.54 (95%
CI 0.35–0.84) for vitamin D. However, when incorpo-
rated into a multivariate model the trends lost statistical
significance and the RR were attenuated [156]. Tseng
et al. evaluated the association between a number of
micronutrients (folate, calcium, iron and antioxidant
vitamin) and the risk of colorectal neoplasia. In this
study, a reduced risk of adenomas was confined to men
in the highest calcium quartile [157]. The associations
between fermented dairy products, calcium intake and
risk of colorectal cancer were evaluated in a population
with a wide variation in intake of dairy product that
participated in the Netherlands Cohort Study of diet
and cancer, through a case-control study that analyzed
data obtained from 215 incident cases of colon cancer
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and 111 of rectal cancer, after 3.3 years of follow-up.
In crude and multivariate models, total dietary calcium
intake (highest vs. lowest quintile, RR 0.92, 95% CI
0.64–1.34) and calcium from fermented dairy products
(RR 1.14, 95% CI 0.77–1.68) were not significantly
associated with colorectal cancer risk [158]. The asso-
ciation between colorectal adenomas and diet were
evaluated in subjects participating in the Nottingham
fecal occult blood screening program. In this study, a
diet history was obtained from 147 patients with col-
orectal adenomas and 153 age and sex matched fecal
occult blood (FOB)-negative and 176 FOB-positive
controls. No association was seen between calcium
intake and adenoma protection [159]. Two additional
case-control studies evaluated the association between
regular usage of supplementation with vitamin A, C,
D and E, or with calcium or multivitamins and the risk
of developing colorectal adenomas (new or recurrent).
No protective effect was documented for any of the
studied variables [160]. Bergsma-Kadijk et al. [161]
provided a quantitative summary of a large number of
epidemiological studies (24 articles reporting 43 mea-
sures of RR) addressing the hypothesis of colorectal
neoplasia protection by dietary calcium. The weighted
mean using a random effects model revealed a RR of
0.89 (95% CI 0.79–1.01). Results obtained from differ-
ent studies showed substantial heterogeneity with the
‘true’ RRs falling between 0.50 and 1.60. Summary
RRs for cohort and case-control studies were 0.90 and
0.88, respectively. Summary RRs for adenomas and
carcinomas were also reported, and calculated at 1.13
(95% CI 0.91–1.39) and 0.86 (95% CI 0.74–0.98),
respectively. Overall the epidemiological data on cal-
cium intake is quite heterogeneous, suggesting a very
modest beneficial effect at best.
Mechanism and preclinical data. A number of mech-
anisms have been postulated in order to explain
the putative chemopreventive effect of calcium in the
gut. Calcium may act through the binding of bile
and fatty acids in the intestinal lumen and decreas-
ing exposure of the large bowel epithelium to these
substances. Bile and fatty acids may display toxic
effects to the colonic epithelium which may result
in primary increases in cell proliferation or alterna-
tively in compensatory hyperproliferation secondary
to repair responses [162]. In either case, increased
proliferation may ultimately lead to carcinogenesis of
the colonic epithelium. Calcium may also act through
the induction of terminal differentiation of colonic
epithelial cells [163]. In preclinical in vivo studies
using rodent models of chemical carcinogenesis (pro-
moted by high fat diets), calcium administration was
associated with a protective effect against colorectal
carcinogenesis (decrease proliferation and decrease
tumor formation) [164].
Human studies. Some but not all the clinical studies
have demonstrated an anticarcinogenic effect as a result
of calcium supplementation. Lipkin et al. studied the
frequency and distribution of proliferating epithelial
cells lining the colonic crypts in 10 subjects at high risk
for familial colon cancer. The patterns of cell prolifer-
ation were evaluated before and after supplementation
of their usual diets with 1.25 g of calcium as calcium
carbonate. After 2 to 3 months of calcium supplemen-
tation, the investigators found a substantial reduction
in epithelial proliferation indicating a beneficial effect
[165]. The results of three clinical trials were reported
by Wargovich et al. These small studies evaluated the
effect of calcium supplementation (calcium carbonate)
on rectal epithelial proliferation in subjects with his-
tory of sporadic adenomas. In 6 participants, 3-month
supplementation with 1500 mg of calcium carbonate
failed to suppress proliferation in normal appearing
mucosa (thymidine labeling). A daily dose of 2000 mg
was, however, associated with a substantial reduction
after 30 days. A small randomized placebo-controlled
study of calcium was then conducted and revealed
a marked suppression of rectal proliferation with
calcium administration [166]. A randomized double-
blinded, placebo-controlled study of supplemental
calcium was conducted in familes with hereditary
nonpolyposis colorectal cancer. A total of 30 subjects
participated in the study. Study participants received
1.5 g of calcium carbonate or placebo three times a
day for a total of 12 weeks. No substantial differences
were seen in epithelial cell proliferation determined
by labeling index of whole crypts and crypt compart-
ments by 5-bromo-2′-deoxyuridine [167]. Thirty-one
patients with familial polyposis, after subtotal colec-
tomy, were randomized to placebo or to supplementa-
tion with 1200 mg of calcium daily. The intervention
was given for 9 months, and the patients underwent
evaluations that included food questionnaires, mea-
surement of fecal pH as well as calcium and bile
acid content. Rectal biopsies were also obtained and
assessed for epithelial proliferation using thymidine
labeling. Fecal pH, weight and bile acid levels were
similar before intervention and remained unchanged.
Fecal calcium levels were similar before the inter-
vention in both groups but progressively increased in
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the calcium group. No substantial differences were
observed in rectal epithelial proliferation between the
two groups [168]. A randomized placebo-controlled
study reported no effect of calcium supplementation on
rectal mucosal proliferation in patients with previous
large-bowel adenomas [169]. The effects of calcium
supplementation on bile acid content have been eval-
uated clinically. Two different studies documented
beneficial calcium-induced changes in bile acid com-
position, which were characterized by a decrease in
total as well as secondary bile acids levels in feces
[170,171]. A recently completed randomized placebo-
controlled phase III study has been reported by Baron
et al. In this study, 930 patients with a history of col-
orectal adenomas were randomized to receive 3 g of
calcium carbonate (1200 mg of elemental calcium) or
placebo [172]. A moderate (20%) but statistically sig-
nificant reduction in the incidence of new adenomas
was seen in the cohort receiving calcium supplemen-
tation. Overall, the beneficial effects of calcium on
colorectal carcinogenesis seem to be modest.
V.B.2. Fiber
Epidemiology. Fiber is another dietary component
that has received substantial attention as a possible
chemopreventive agent against colon cancer. Eco-
logical studies reported in the 1970s suggested that
colorectal cancer incidence in selected populations
may relate to the composition of their diet, with
diets containing high fiber content being protective
[173,174]. The epidemiology of fiber and colon can-
cer protection is extensive and has been reviewed
elsewhere [175].
Mechanisms. It was postulated that dietary fiber may
exert protective effects through a number of mecha-
nisms. Increased fiber content may result in the dilu-
tion of potential dietary carcinogens through the pro-
motion of increase fecal bulk [174]. Fiber may also
bind bile acids, which may be carcinogenic, and may
also indirectly affect bile acid conversion in the large
bowel from primary to secondary bile acids by induc-
ing a more acidic environment due to its increased
bacterial fermentation in the gut [176,177]. Further-
more, increased delivery of the fermentable compo-
nent of fiber (also known as ‘resistant starch’) to the
large bowel lumen, results in the increase production
of short-chain fatty acids through its fermentation by
bacteria present in the gut [178]. Short-chain fatty acids
such as butyrate may have anticarcinogenic effects in
the colorectal epithelium [179].
Human studies. Although a number of case-control
studies and at least two meta-analyses have suggested a
protective effect for dietary fiber, most of the presently
available cohort and randomized studies do not sup-
port this hypothesis [180]. A study conducted by the
Phoenix Colon Cancer Prevention Physicians’ Net-
work accrued 1429 patients with a history of resected
adenomas and randomized them to two different levels
of daily wheat bran supplementation (2.5 g vs. 13.5 g)
[181]. No differences in adenoma recurrence rates were
found between the two groups. The second study, the
Polyp Prevention Trial, enrolled a total of 2079 par-
ticipants with a history of colorectal adenomas [182].
The subjects were randomized to an active interven-
tion (dietary counseling coupled with a low-fat, high-
fiber diet) or to a control group (no counseling plus
usual diet). Again, no differences were observed in
adenoma recurrence between the two groups at 1 and
at 4 years after the initiation of the intervention. Cur-
rently, the available prospective and randomized data
do not support the hypothesis of colorectal cancer
chemoprevention by fiber.
V.B.3. Folate
Epidemiology. Folate is an essential element in the
human diet that plays important biological roles.
Folates participate in the regeneration of methionine
and are involved in the production of purines and
pyrimidines, which are required for the synthesis of
DNA. Inadequate intake of folate may result in abnor-
malities in DNA synthesis and/or repair as well as in
changes in DNA methylation, all of which may predis-
pose to colorectal carcinogenesis. The epidemiologic
evidence suggests an association between inadequate
intake of folic acid and colorectal cancer occurrence.
The relationship between folate status and colorectal
cancer was evaluated in a case-control study nested
within the Alpha-Tocopherol Beta Carotene Study
cohort of male smokers 50–69 years of age. Serum
folate was measured in 144 incident cases (colorectal
cancer) and in 276 age- and clinic-matched controls.
The time of blood collection was the same between
the groups. Baseline dietary folate information was
available from a food questionnaire for 92% of these
men. No statistically significant association was seen
between serum folate levels and colorectal cancer. The
results of dietary intake of folate proved protective. The
odds ratios were as follows: 0.40 (95% CI 0.20–1.31),
0.16 (95% CI 0.13–0.88) and 0.51 (95% CI 0.20–1.31)
for the second, third and fourth quartiles of energy
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adjusted folate intake, respectively, when compared
to the first [183]. The relationship between vitamin
supplement used and colon cancer was assessed in
another case-control study. Two hundred and fifty-one
men and 193 women who had been diagnosed with
colon cancer were identified through the Surveillance,
Epidemiology and End Results (SEER) cancer reg-
istry, and were used as cases. Frequency, duration and
dose per day of supplement use was assessed during
the 10 years prior to cancer diagnosis, ending 2 years
before the cancer was found. The average daily intake
of supplemental folate was associated with reduced
colon cancer. Other supplements also were associated
with protective effects in this study [184]. Additional
epidemiologic studies have also suggested a protec-
tive effect either singly or in association with other
factors such as alcohol [185,186]. Smaller explorative
case-control studies have also found protective effects
in cohorts of patients with inflammatory bowel dis-
ease. A case control study was conducted in a cohort
of patients with ulcerative colitis at the University
of Chicago. This study was designed to evaluate the
effects of folate supplementation on the risk of dys-
plasia or cancer in ulcerative colitis patients. Data
was collected from records obtained from 99 patients
with diagnoses of pancolitis for periods longer than 7
years. Thirty-five patients with neoplasia were com-
pared with 64 patients in whom dysplasia was never
found to assess the effect of folate supplementation on
the rate of neoplastic development. A protective asso-
ciation (62% lower incidence) was seen with folate
supplementation [RR 0.38 (95% CI 0.12–1.20)] [187].
A second case-control study published by the same
group was consistent with those findings as it demon-
strated an increased risk for dysplasia or cancer in
association with depressed RBC folate [odds ratio 0.82
(95% CI 0.68–0.99)] [188]. Thus, the epidemiology of
folate use and colon cancer risk supports a protective
association. It remains unclear, however, whether folic
acid intake above that required to prevent deficiency is
associated with additional protection.
Mechanisms. Folic acid and its metabolites 5,10-
methylenetetrahydrofolate and 5-methylhydrofolate
are critical to proper DNA synthesis. 5,10-
methylenetetrahydrofolate is converted to 5-methyl-
tetrahydrofolate by the enzyme methylenetetrahydro-
folate reductase (MTHFR). 5-methyltetrahydrofolate
then serves as a methyl donor during the conversion of
homocystein into methionine by methionine synthase
(MS). MTHFR and MS polymorphisms have been
described which may be associated with protection
against colon cancer in patients with adequate inges-
tion of folate [189,190]. Methionine is a precursor of
S-adenosyl-methionine, which acts as a major donor
of methyl groups in vivo. Decrease production of
S-adenosyl-methionine may result in abnormal DNA
methylation (hypomethylation) which may contribute
to carcinogenesis [191,192].
Human studies. Giovannucci evaluated the association
between high alcohol plus methyl deficient diets (low
folate and low methionine) and colon cancer risk. They
analyzed dietary data obtained from a cohort of 47,931
male health professionals. After 6 years of follow-up
in this large cohort, 205 new cases of colon cancer
were diagnosed and their dietary data was used for pur-
poses of this study. Current alcohol intake was associ-
ated with increased risk [RR 2.07 (95% CI 1.29–3.32)]
for >2 drinks versus less or equal than 0.25 drinks
per day. Folate and methionine intakes were weakly
associated with increased risk. However, striking asso-
ciations were seen for combinations of high alcohol
ingestion and low intakes of methionine and folate.
The RR for total colon cancer was 3.30 (95% CI 1.58–
6.88). These findings suggeted that important interac-
tions existed between alcohol, methionine and folate
[193]. Data obtained from another large prospective
study, the Nurses’ Health Study, suggested that sup-
plementation with high daily doses of folate are pro-
tective against colorectal cancer. In this report, higher
energy-adjusted folate intake was related to a lower
risk of colorectal cancer with a RR of 0.69 (95% CI
0.52–0.93). Risk reduction became statistically signifi-
cant only after 15 years of use [RR 0.25 (95% CI 0.13–
0.51)], suggesting that long consumption times may
be required to see an effect and also, that the chemo-
preventive effect of folate may take place early on
during the carcinogenesis process [194]. A few small
biomarker-driven studies have also been completed.
Kim et al. evaluated the effects of folate supplemen-
tation on genomic DNA methylation and DNA strand
breaks in exons 5–8 of the p53 gene of the colonic
mucosa of 20 patients with adenomas that were ran-
domized to receive folate (5 mg/day) or placebo for
1 year after polypectomy. Biomarker measurements
occurred at baseline, 6 months and after 1 year. Folate
levels in serum, red blood cells (RBC) and colonic
mucosa were also measured. Folate supplementation
was associated with increases in serum, RBC and
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colonic mucosal folate concentrations (P < 0.002).
More rapid changes (increase) in methylation were
seen in the group supplemented with folate as well as a
decrease in the extent of p53 strand breaks. This ‘pos-
itive’ changes were realized at 6 months in the inter-
vention group, although improvement was also seen in
the placebo group, but only after a year [195]. Overall
these data suggest a possible protective effect for folate
in populations at increased risk for colon neoplasms.
In addition, although further validation is required,
folate supplementation may be of particular interest in
patients with long-standing inflammatory bowel dis-
ease. We are not aware of any reports of Phase III stud-
ies with folate as the main intervention and adenoma
recurrence or cancer incidence as the main endpoints.
V.B.4. New nutritionally-derived
chemopreventive agents
A number of dietary components have demonstrated
interesting chemopreventive activity on a variety of
preclinical models of colorectal carcinogenesis.
Organic selenium compounds appear to be active
colorectal chemopreventive agents. P -methoxy-
benzyl selenocyanate and 1,4-phenylenebis
(methylene)selenocyate are two synthetic organose-
lenium compounds which demonstrated substantial
protective activity on a rat chemical colorectal car-
cinogenesis model [196]. Two citrus extracts, perillyl
alcohol and auroptene have also been found to reduce
tumor incidence and multiplicity in chemical carcino-
genesis rodent models [197,198]. The monoterpenoid
perillyl alcohol is a metabolic derivative of d-limonene
which is present in citrus fruits and other dietary com-
ponents. Its proposed mode action involves the inter-
ference with isoprenylation of small cellular proteins
such as p21ras. The mechanism of action of auroptene
is not fully understood but may involve the induction
of phase II metabolic enzymes (blocking activity)
as well as the interference with polyamine produc-
tion through the inhibition of ODC. Other interesting
leads under development include the xanthine oxidase
inhibitor 1′-acetoxychavicol acetate which is present
in the seeds or rhizome of Langunas galanga, and the
naturally occurring flavonoids diosmin and hesperidin
[199,200].
Curcumin, a component of turmeric, deserves
special attention. This compound has displayed sub-
stantial chemopreventive activity in animal models
of colorectal carcinogenesis [201]. It may exert its
anticarcinogenic effects through a number of poten-
tial mechanisms which include the modulation of
COX, modulation of LOX, antiangiogenic activity and
antioxidant properties [201,202]. Curcumin’s actions
on prostanoid metabolism likely involve the mod-
ulation of the nuclear factor κB pathway (NFκB).
Curcumin has strong antiproliferative effects on estab-
lished human colon cancer cell models [203]. Pre-
clinical and early clinical pharmacology suggest that
curcumin is poorly absorbed through the gastrointesti-
nal tract, making it an attractive compound for use as a
chemopreventive of gastrointestinal malignancy [204].
A phase Ia study of a well-defined curcumin prepara-
tion is in progress at the University of Michigan and a
phase Ib study is in the planning phase.
V.C. Hormones
Epidemiology. Epidemiological data shows a decrease
in colorectal cancer mortality in both genders but
more substantially in women [205,206]. Grodstein
conducted a metaanalytical assessment of the epi-
demiologic literature. Data from 18 epidemiological
studies of postmenopausal hormone therapy and col-
orectal cancer were pooled and analyzed. A 20%
reduction in risk of colon cancer was observed [RR
0.81 (95% CI 0.74–0.86)]. Much of the reduction in
risk was limited to current hormone users [RR 0.66
(95% CI 0.59–0.74)] [207]. Hormonal differences
have been proposed as an explanation for these dif-
ferences. Hormone-replacement therapy (HRT) in
postmenopausal women and its effects in colorectal
cancer endpoints have been evaluated in a handful of
studies. Post-menopausal use of hormones was asso-
ciated with a significant decrease in colorectal cancer
mortality in the Cancer Prevention Study II with an
overall RR of 0.71 [208]. The degree of protection
was higher with current use and with continued use
for very long periods of time (over 11 years). In the
Nurses’ Health Study, a protective effect (decrease
in colorectal cancer incidence) was documented with
current HRT use. The overall reduction in risk was
estimated at 35%. Meta-analytical studies support a
protective effect with similar (moderate) levels of pro-
tection. The Nurses’ Health Study also evaluated the
effects of HRT on colon adenoma formation [209].
Hormone replacement therapy was protective against
the development of large size adenomas, suggesting
that estrogen protective effects may occur during the
later phases of carcinogenesis (late adenoma stage).
Postulated mechanisms. Estrogen may exert anti-
carcinogenic effects in the colon through a number
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of possible mechanisms which include a reduction
in the production of secondary bile acids, inhibi-
tion of insulin-like growth factor levels or through
direct effects on the colorectal epithelium [210,211].
A recent molecular epidemiological study suggested
that modulation of MSI may in part explain estrogen’s
anticarcinogenic effects [212].
Preclinical data. A large body of preclinical informa-
tion has documented the presence of estrogen receptors
(ER) in established human cell lines, with a predom-
inance in estrogen receptor beta isoforms [213,214].
Tumors from patients with primary colon cancers have
also shown to express ER [215]. Estrogen analogues
as well as selective estrogen receptor modulators
(SERMs) have produced substantial inhibition in cell
growth of established human colon cancer cell lines
in vitro [216–218]. A number of mechanistic in vitro
studies are currently undergoing in order to better elu-
cidate the nature of this effects. These studies have
supported the involvement of the ER in the regulation
of colon cancer cell growth, and have suggeted that
signaling through ER-β may be important [219,220].
Preclinical in vivo studies have started to look into
the effects of estrogenic compounds or SERMs on
colon carcinogenesis in chemically-induced rodent
models. Ziv et al. studied the effects of tamoxifen on
1,2-dimethylhydrazine (DMH)–HCl-induced colon
carcinogenesis in rats. In this study the incidence of
DMH-induced colon cancer in rats was reduced by
tamoxifen. Whether these effects reflect modulation of
estrogen-dependent pathways or were induced through
estrogen-independent mechanisms is not clear [221].
Smirnoff et al. reported on the protective effect of estro-
gen against DMH-induced murine colon carcinogen-
esis. Tumor multiplicity was significantly decreased
by estrogen. In addition, these protective effects were
associated with a marked increase in vitamin D recep-
tor (VDR) mRNA and protein expression in normally
appearing colonic mucosa. These effects were associ-
ated with significant decreases in methylation density
of CpG islands in the VDR gene, suggesting that some
of the protective effects may relate to reversion of
VDR gene silencing. Serum vitamin D and parathy-
roid hormone levels remained unaffected [222].
Human studies. To our knowledge there are no reports
of prospective human chemoprevention studies of
estrogenic modulation in high-risk populations for
colorectal cancer.
V.D. Polyamine inhibitors
Mechanisms. The polyamines (spermine, spermidine
and putrescin), are essential for normal cell growth.
The rate-limiting enzyme associated with the synthesis
of polyamines is ODC [223]. A number of factors asso-
ciated with cellular transformation are known inducers
of ODC. In addition, suppression of polyamine pro-
duction through the modulation of ODC results in cell
growth inhibition. ODC and the polyamine pathway
seem to have an important role in carcinogenesis and
their modulation may be associated with a chemopre-
ventive effect [224]. DFMO is the main representative
of a class of compounds capable of inhibiting ODC
activity.
Preclinical data. DFMO has demonstrated anticar-
cinogenic activity in in vitro cell transformation assays
as well as in in vivo chemical carcinogenesis models.
DFMO is also capable of suppressing cell proliferation
in human colon cancer cell models and has displayed
inhibitory effects on ACF systems [225,226]. Pro-
tective effects in most of these systems have been
associated with profound inhibition of ODC activ-
ity and substantial depletion of polyamines. Other
agents, that seem to act through multiple mecha-
nisms, may also concede anticarcinogenic protection,
partly, through the modulation of polyamine levels in
intestinal mucosa. Soy protein-rich diets, for instance,
were found to reduce mucosal polyamines in male
Wistar rats.
Human studies. A phase I study was completed by
Love et al. [227] which reported dose limiting ototox-
icity for DFMO with doses greater than 1 g/m2. Sub-
sequently, the same group of investigators conducted
a placebo-controlled trial of DFMO in individuals at
risk for colorectal cancer (personal history of resected
adenomatous polyps or strong family history of colon
cancer). The main goals were to assess the effects of
this compound on polyamine and ODC levels in differ-
ent segments of the colorectal mucosa and to evaluate
the toxicity associated with 1-year treatment. DFMO
was administered at 0.5 g/m2/day as a single oral dose.
Significantly, decreased levels of putrescine and sper-
midine were found in the rectosigmoid mucosa of indi-
viduals treated with DFMO. Similar trends were seen
in other anatomical segments (rectum and cecum) but
did not reach statistical significance. Modulation of
polyamines were observed as early as 3 months after
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the initiation of DFMO and persisted until the end of
the study. The most worrisome side-effect was hear-
ing loss (12.5%). This was both subjectively reported
and audiologically confirmed. Given the hearing side-
effects associated with this regimen, the investigators
suggested that alternative schedules would need to be
evaluated prior to proceeding to phase III studies [228].
A short-term phase IIa trial reported by Meyskens et al.
[229] demonstrated that DFMO given at doses as low
as 0.10 g/m2 per day was able to inhibit polyamine pro-
duction in rectal mucosa after only 1 month. Based on
these results a follow-up study was designed in order to
establish whether polyamine content in rectal mucosa
could be suppressed (without a rebound) for 1 year
with doses lower than 0.5 g/m2. The investigators con-
cluded that a dose of 0.50 g/m2 was safe and effective,
and they recommended this dose level of administra-
tion for use in combination phase IIb or single-agent
phase III chemoprevention trials [230].
V.E. Other agents
Other agents have displayed chemopreventive effects
against colorectal carcinogenesis in a variety of exper-
imental systems. These include the dithione oltipraz,
the polyphenol ellagic acid, anethole trithione, dial-
lyl disulfide, butylated hydroxyanisole, purpurin, ritin,
butyrate, isothiocyanates, phenyl-3-methyl caffeate
and other agents. These agents are being evaluated in
animal models and some are undergoing phase I testing
at this point.
VI. Future directions
Targeted therapeutics. Substantial progress has been
made in our understanding of colorectal premalignancy
and colon cancer genesis. The molecular genetic mod-
els of colorectal carcinogenesis have grown progres-
sively more complex, offering a more detailed albeit
incomplete picture of the critical mechanisms that
underline the transformation of colonic epithelial cells.
A number of targeted therapies have been developed
and are currently being tested in established human
malignancies. The demonstration of substantial ther-
apeutic activity associated with the administration of
the targeted agent STI-571 in chronic myelogenous
leukemia (CML) and in the highly chemotherapy-
resistant gastrointestinal stromal tumors (GIST), has
provided impetus to this new paradigm [231]. The case
of CML may be of relevance to chemoprevention, as
STI-571 is substantially more active during the early
stages of the disease (chronic phases) and its efficacy
is compromised as additional molecular abnormalities
are acquired by the malignant clone. As Vogelstein
et al. had suggested, fewer molecular abnormalities
seem to be required for the development of colon
premalignancy (adenomas) [8].
The procurement of new active leads for testing as
colorectal cancer chemopreventives will likely involve
the redirection of some of the novel targeted agents
currently under clinical evaluation in cancer therapeu-
tics for testing as modulators of premalignancy, when
mechanistically appropriate. Good examples include
the modulators of growth factor receptors, farnesyl
transferase inhibitors, modulators of lipooxigenase
and inhibitors of angiogenesis. The immunology of
colon premalignancy still remains an untapped field
in colorectal cancer chemoprevention that deserves
attention [232].
Combination chemoprevention. Given the redun-
dancy of signal transduction regulatory mechanisms
in transforming or transformed cells, it is reasonable
to believe that a single agent will not be sufficiently
active to slow or reverse neoplastic transformation.
For this reason, combinations of synergistically active
chemopreventive agents are contemplated in the future.
An interesting example of a rationale combination of
chemopreventive agents might be the combination of
a COX-2 inhibitor and an epidermal growth factor
receptor inhibitor. Preliminary in vitro data suggest
strong synergism between blocking the epidermal
growth factor receptor and COX-2 enzyme [233–235].
EGFR stabilizes COX-2 expression in this model
[233,234]. Indeed, in vivo data demonstrate strong
anticarcinogenesis synergism between COX inhibition
and EGFR inhibition in chemical carcinogenesis mod-
els [236,237]. Synergistic combinations of NSAIDs
and the polyamine inhibitor DFMO are currently under
clinical testing [238,239]. It is reasonable to predict
that mechanistically based combinations of chemopre-
ventive agents that target different, yet related signal
transduction pathways that control cellular prolifera-
tion and apoptosis, offer great promise.
Foodstuffs as chemopreventives. Nature offers a large
if not the largest drug procurement potential. Yet,
chemoprevention development with nutritional agents
has followed two distinct pathways – identifying, iso-
lating, purifying and creating ‘drugs’ from foodstuffs
that appear to be cancer protective in epidemiology
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studies or diet modification. Chemoprevention trials of
micronutrients identified and tested in this manner have
been disappointing. Recent data from the Stoner lab-
oratory suggest that foodstuffs can be grown remark-
ably uniformly from year to year. These food stuffs
(strawberries, black raspberries) contain large quanti-
ties of micronutrients known to be cancer protective
(calcium, ellagic acid, ferulic acid and β-sitosterol).
The concentrations of calcium, ellagic acid, ferulic acid
and β-sitosterol in lyophilized black raspberries stud-
ied by Dr. Stoner’s group [240] were 167, 200, 72
and 21 mg/kg respectively in a 10% black raspberry
diet. Yet, in similar chemically induced models where
inhibition of colon tumors or ACF were observed, the
minimum effective concentrations of these compounds
were 500, 8,000, 2,000 and 500 mg/kg, respectively
[241–243]. This suggests that low levels of multi-
ple compounds, such as those naturally present in
black raspberries and strawberries, may have sub-
stantial chemopreventive effects. The use of multi-
ple compounds at low doses, especially with different
mechanisms of action, is attractive because it reduces
the possibility of toxicity related to large doses of single
compounds. As individual food components are tested
for chemopreventive activity in model systems, it is
logical to look for foods that naturally contain multiple
components and to test the effects of a whole food con-
taining them in a single system. Thus, the identification
of foodstuffs with chemopreventive properties offers
a unique opportunity for simplified multiagent ther-
apy through the administration of well-standardized
whole foods (as suppose to purified compounds). Fruits
and vegetables when administered whole may help to
deliver a number of potentially active chemopreven-
tives in one single intervention.
References
1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer sta-
tistics. CA Cancer J Clin 50: 7–33, 2000
2. Osborne M, Boyle P, Lipkin M: Cancer prevention. Lancet
349(Suppl II): 27–30, 1997
3. Verno SW: Participation in colorectal cancer screening:
A review. J Natl Cancer Inst 89: 1406–1422, 1997
4. Wattenberg LW: An overview of chemoprevention: Current
status and future prospects. Proceedings of the Society for
Experimental Biology and Medicine 216: 133–141, 1997
5. Lippman S, Lee J, Sabini A: Cancer chemopreven-
tion: Progress and promise. J Natl Cancer Inst 90(20):
1514–1518, 1998
6. Heinonen O, Albanes D: The effect of vitamin E and beta-
carotene on the incidence of lung cancer and other cancers
in male smokers. N Engl J Med 330: 1029–1035, 1994
7. Omen G, Goodman G, Thornquist M, Balmes J, Cullen M,
Glass AK, et al.: Effects of a combination of beta carotene
and vitamin A on lung cancer and cardiovascular disease.
N Engl J Med 334(18): 1150–1155, 1996
8. Fearon ER, Vogelstein B: A genetic model for colorectal
tumorigenesis. Cell 61: 759–767, 1990
9. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH,
Maziarz FR, et al.: Association of the APC gene product
with β-catenin. Science 262: 1731–1734, 1993
10. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H,
Horii A, et al.: Mutations of chromosome 5q21 genes in
FAP and colorectal cancer patients. Science 253: 665–669,
1991
11. Groden J, Thliveris A, Samowitz W, Carlson M, Gilbert L,
Albertsen H, et al.: Identification and characterization of
the familial adenomatous polyposis coli gene. Cell 66:
589–600, 1991
12. Fearnhead NS, Britton MP, Bodmer WF: The ABC of APC.
Human Molec Genet 10(7): 721–733, 2001
13. Hiltunen MO, Alhonen L, Koistinaho J, Myohanen S,
Paakkonen M, Marin S, Kosma VM, Janne J: Hypermethy-
lation of the APC (Adenomatous Polyposis Coli) gene pro-
moter region in human colorectal carcinoma. Int J Cancer
70: 644–648, 1997
14. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P:
Regulation of intracellular beta-catenin levels by the ade-
nomatous polyposis coli (APC) tumor suppressor protein.
Proc Natl Acad Sci USA 92: 3046–3050, 1995
15. Hulsken J, Birchmeier W, Behrens J: E-cadherin and APC
compete for the interaction with beta-catenin and the
cytoskeleton. J Cell Biol 127: 2061–2069, 1995
16. Korinek V, Barker N, Morin PJ, van Wichen D, deWeger R,
Kinzler KW, et al.: Constitutive transcriptional activation
by a beta-catenin-Tcf complex in APC-1-colon carcinoma.
Science 275: 1784–1787, 1997
17. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H,
Vogelstein B, Kuzler KW: Activation of beta-catenin-Tcf
signaling in colon cancer by mutations in beta-catenin or
APC. Science 275: 1787–1790, 1997
18. Funk CD, Funk LB, Kennedy ME, Pong AS,
Fitzgerald GA: Human platelet/erythroleukemia
prostaglandin synthase: cDNA cloning, expression, and
gene chromosomal assignment. FASEB J 5: 2304–2312,
1991
19. Sigal E: The molecular biology of mammalian arachidonic
acid metabolism. Am J Physiol 260: L13–L28, 1991
20. Sirois J, Richards J: Purification and characterization of a
novel, distinct isoform of prostaglandin endoperoxide syn-
thase induced by human chorionic gonadotrophin in gran-
ulosa cells of rat preovulatory follicles. J Biol Chem 267:
6382–6388, 1992
21. Herschman H: Prostaglandin synthase 2. Biochim Biophys
Acta 1299: 125–140, 1996
22. Sano H, Kawahito Y, Wilder R, Hashiramoto A, Mukai S,
Asai K, et al.: Expression of cyclooxygenase-1 and -2 in
human colorectal cancer. Cancer Res 55: 3785–3789, 1995
23. Kargman S, O’Neill S, Vickers P, Evans J, Mancini J,
Jothy S: Expression of prostaglandin G/H synthase-1
and -2 protein in human colon cancer. Proc AACR 36: 601,
1995
341
24. Hecht J, Rovai L, Herschman H: Cyclooxygenase-2
expression and regulation in colonic mucosa, cancer, and
cell lines. Proc AACR 36: 598, 1995
25. Eberhart C, Coffey R, Radhika A, Giardiello F,
Ferrenbach S, DuBois R: Up-regulation of
cyclooxygenase 2 gene expression in human colorectal
adenomas and adenocarcinomas. Gastroenterology 107:
1183–1188, 1994
26. Subbaramaiah K, Telang N, Ramonetti J, Araki R,
DeVito B, Weksler B, et al.: Transcription of
cyclooxygenase-2 is enhanced in transformed mammary
epithelial cells. Cancer Res 56: 4424–4429, 1996
27. Boolbol S, Dannenberg A, Chadburn A, Martucci C,
Guo X, Ramonetti J, et al.: Cyclooxygenase-2 overexpres-
sion and tumor formation are blocked by sulindac in a
murine model of familial adenomatous polyposis. Cancer
Res 56: 2556–2560, 1996
28. Oshima M, Dinchuk J, Kargman S, Oshima H, Hancock B,
Kwong E, et al.: Suppression of intestinal polyposis in
Apc 716 knockout mice by inhibition of cyclooxygenase 2
(COX-2). Cell 87: 803–809, 1996
29. DuBois R, Awad J, Morrow J, Roberts L, Bishop P:
Regulation of eicosanoid production and mitogenesis in rat
intestinal epithelial cells by transforming growth factor–
alpha and phorbol ester. J Clin Invest 93: 493–498, 1994
30. Tsujii M, DuBois R: Alterations in cellular adhesion and
apoptosis in epithelial cells overexpressing prostaglandin
endoperoxide synthase 2. Cell 83: 493–501, 1995
31. Thiagalingam S, Lengauer C, Leach FS, Schutte M,
Hahn SA, Overhauser J, et al.: Evaluation of candidate
tumor suppressor genes on chromosome 18 in colorectal
cancers. Nat Genet 13: 343–346, 1996
32. Fazeli A, Dickinson SL, Hermiston ML, Tighe RV,
Steen RG, Small CG, et al.: Phenotype of mice lacking
functional deleted in colorectal cancer (Dcc) gene. Nature
386: 796–804, 1997
33. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA,
Garber J, et al.: The human mutator gene homolog MSH2
and its association with hereditary nonpolyposis colon
cancer. Cell 75: 1027–1038, 1993
34. Leach FS, Nicolaides NC, Papadopoulos N, Liv B, Jen J,
Parsons R, et al.: Mutations of a mutS homolog in hered-
itary nonpolyposis colorectal cancer. Cell 75: 1215–1225,
1993
35. Brenner CE, Baker SM, Morrison PT, Warren G, Smith LG,
Lescoe MK, et al.: Mutation in the DNA mismatch repair
gene homologue hMLH1 is associated with hereditary non-
polyposis colon cancer. Nature 368: 258–261, 1994
36. Thibodeau SN, French AJ, Cunningham JM, Tester D,
Burgart LJ, Roche PC, et al.: Microsatellite instability
in colorectal cancer: Different mutator phenotypes and
the principal involvement of hMLH1. Cancer Res 58:
1713–1718, 1998
37. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L,
Lutterbaugh J, et al.: Inactivation of the type II TGF-beta
receptor in colon cancer cells with microsatellite instability.
Science 268: 1336–1338, 1995
38. Souza RF, Lei J, Yin J, Appel R, Zon TT, Zhou X,
et al.: A transforming growth factor beta 1 receptor
type II mutation in ulcerative colitis associated neoplasms.
Gastroenterology 112: 40–45, 1997
39. Massague J: The transforming growth factor beta family.
Annu Rev Cell Biol 6: 597–641, 1990
40. Massague J, Polyak K: Mammalian antiproliferative sig-
nals and their targets. Curr Opin Genet Dev 5(1): 91–96,
1995
41. Alexandrow M, Moses H: Transforming growth factor beta
and cell cycle regulation. Cancer Res 55: 1452–1457, 1995
42. Oberhammer F, Pavelka M, Sharma S, Tiefenbacher R,
Purchio A, Bursch W, Shulte-Hermann R: Induction of
apoptosis in cultured hepatocytes and in regressing liver
by transforming growth factor beta 1. Proc Natl Acad Sci
USA 89: 5408–5412, 1992
43. Rorke E, Jacobberger J: Transforming growth factor-beta 1
(TGF beta 1) enhances apoptosis in human papillomavirus
type 16-immortalized human ectocervical epithelial cells.
Exp Cell Res 216: 65–72, 1995
44. Lin H, Wang XF, Ng-Eaton E, Weinberg R, Lodish H:
Expression cloning of the TGF-beta type II receptor, a
functional transmembrane serine/threonine kinase. Cell 68:
775–785, 1992
45. Wrana J, Attisano L, Carcamo J, Zentella A, Doody J,
Laiho M, Wang X-F, Massague J: TGF-beta signals
through a heteromeric protein kinase receptor complex.
Cell 71: 1003–1014, 1992
46. Moustakas A, Lin H, Henis Y, Plamondon J, O’connor-
McCourt M, Lodish H: The transforming growth factor
beta receptors types I, II and III form hetero-oligomeric
complexes in the presence of ligand. J Biol Chem 268:
22215–22218
47. Boyd F, Massague J: Transforming growth factor beta inhi-
bition of epithelial cell proliferation linked to the expres-
sion of a 53-kDa membrane receptor. J Biol Chem 264:
2272–2278, 1989
48. Laiho M, Weis F, Boyd F, Ignotz R, Massague J:
Responsiveness to transforming growth factor-beta
(TGF-beta) restored by genetic complementation between
cells defective in TGF-beta receptor I and II. J Biol Chem
266: 9108–9112, 1991
49. Laiho M, Weis M, Massague J: Concomitant loss of
transforming growth factor (TGF) – beta receptor types I
and II in TGF-beta-resistant cell mutants implicates both
receptor types in signal transduction. J Biol Chem 265:
18518–18524, 1990
50. Wrana J, Attisano L, Wieser R, Ventura F, Massague J:
Mechanism of activation of the TGF-β receptor. Nature
370: 341–347, 1994
51. Grady W, Myeroff L, Swinker S, Rajput A, Thiagalingam J,
Lutterbaugh J, Neumann A, Brattain M, Chang J, Kim S-J,
Kinzler K, Vogelstein B, Willson J, Markowitz S:
Mutational inactivation transforming growth factor beta
receptor type II in microsatellite stable colon cancers.
Cancer Res 59: 320–324, 1999
52. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L,
Lutterbaugh J, Fan R, Zborowska E, Kinzler K,
Vogelstein B, Brattain M, Willson JKV: Inactivation of
the type II TGF-beta receptor in colon cancer cells with
microsatellite instability. Science 268: 1336–1338, 1995
342
53. Parsons R, Myeroff L, Liu B, Willson JKV, Markowitz S,
Kinzler K, Vogelstein B: Microsatellite instability and
mutations of the transforming growth factor beta type II
receptor gene in colorectal cancer. Cancer Res 55:
5548–5550, 1995
54. Thibodeau S, Bren G, Schaid D: Microsatellite instability
in cancer of the proximal colon. Science 260: 816–819,
1993
55. Ionov Y, Peinado M, Malkhosyan S, Shibata D,
Perucho M: Ubiquitous somatic mutations in simple
repeated sequences reveal a new mechanism for colonic
carcinogenesis. Nature 363: 558–561, 1993
56. Markowitz S: TGF-β receptors and DNA repair genes, cou-
pled targets in a pathway of human colon carcinogenesis.
Biochim et Biophys Acta 1470: M13–M20, 2000
57. Bird R: Observation and quantification of aberrant crypts
in the murine colon treated with a colon carcinogen:
Preliminary findings. Cancer Lett 37: 147–151, 1987
58. Siu I, Pretlow T, Amini S, Pretlow T: Identification of dys-
plasia in human colonic aberrant crypt foci. Am J Pathol
150: 1805–1813, 1997
59. Polyak K, Hamilton S, Vogelstein B, Kinzler K: Early alter-
ation of cell-cycle-regulated gene expression in colorectal
neoplasia. Am J Pathol 149: 381–387, 1996
60. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S,
Sakamaki S, et al.: Aberrant crypt foci of the colon as
precursors of adenoma and cancer. N Engl J Med 339:
1277–1284, 1998
61. Jen J, Powell S, Papadopoulos N, Smith K, Hamilton S,
Vogelstein B, et al.: Molecular determinants of dysplasia
in colorectal lesions. Cancer Res 54: 5523–5526, 1994
62. Pretlow T, Brasitus T, Fulton N, Cheyer C, Kaplan E: K-ras
mutations in putative preneoplastic lesions in human colon.
J Natl Cancer Inst 85: 2004–2007, 1993
63. Smith A, Stern H, Penner M, Hay K, Mitri A, Bapat B, et al.:
Somatic APC and K-ras codon 12 mutations in aberrant
crypt foci from human colons. Cancer Res 54: 5527–5530,
1994
64. Hamilton S: Pathogenesis of polyps (adenomas). Dis Colon
Rectum 26: 413–414, 1983
65. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M:
Inhibition of aberrant crypt growth by non-steroidal anti-
inflammatory agents and differentiation agents in the rat
colon. Int J Cancer 60(4): 515–519, 1995
66. Reddy B, Rao C, Seibert K: Evaluation of a
cyclooxygenase-2 inhibitor for potential chemopreven-
tive properties in colon carcinogenesis. Cancer Res 56:
4566–4569, 1996
67. Kawamori T, Rao C, Seibert K, Reddy B: Chemopreventive
effect of celecoxib, a specific cyclooxygenase-2 inhibitor
on colon carcinogenesis. Cancer Res 58: 409–412, 1998
68. Konstantakos A, Siu I, Pretlow T, Stellato T, Pretlow T:
Human aberrant crypt foci with carcinoma in situ from a
patient with sporadic colon cancer. Gastroenterology 111:
772–777, 1996
69. Thurnherr N, Deschner EE, Stonehill EH, Lipkin M:
Induction of adenocarcinomas of the colon in mice by
weekly injections of 1,2-dimethylhydrazine. Cancer Res
33: 940–945, 1973
70. Narisawa T, Sato T, Hayakawa M, Sakuma A, Nakano H:
Carcinoma of the colon and rectum of rats by rectal
infusion of N -methyl-N -nitro-N -nitroguanidine. Gann 62:
231–234, 1971
71. Rogers KJ, Pegg AE: Formation of o6-methylguanine by
alkylation of rat liver, colon and kidney DNA following
administration of 1,2-dimethylhydrazine. Cancer Res 37:
4082–4087, 1977
72. Moon RC, Fricks CM, Schiff LJ: Effects of age and sex
on colon carcinogenesis. Proc Am Assoc Cancer Res 17:
23–28, 1976
73. Winneker RC, Tompkins M, Westenberger P, Harris J:
Morphological studies of chemically induced colon
tumours in hamsters. Exp Mol Pathol 27: 19–34, 1977
74. Pozharisski KM, Kapustin YM, Likhachev AJ,
Shaposhnicov JD: The mechanism of carcinogenic action
of 1,2-dimethylhydrazine in rats. Int J Cancer 15: 673–683,
1975
75. Ward JM, Yamamoto RS, Brown CA: Pathology of
intestinal neoplasm and other lesions in rats exposed to
azoxymethane. J Natl Cancer Inst 51: 1029–1039, 1973
76. De Filippo C, Caderni G, Bazzicalupo M, Briani C,
Giannini A, Fazi M, Dolara P: Mutations of the Apc
gene in experimental colorectal carcinogenesis induced by
azoxymethane in F344 rats. Br J Cancer 77: 2148–2151,
1998
77. Maltzman T, Whittington J, Driggers L, Stephens J, Ahnen
D: AOM-induced mouse colon tumors do not express full-
length APC protein. Carcinogenesis 18(12): 2435–2439,
1997
78. Bissonnette M, Khare S, von Lintig FC, Wali RK,
Nguyen L, Zhang Y, Hart J, Skarosi S, Varki N,
Boss GR, Brasitus TA: Mutational and nonmutational acti-
vation of p21ras in rat colonic azoxymethane-induced
tumors: Effects on mitogen-activated protein kinase,
cyclooxygenase-2 and cyclin D1. Cancer Res 60(16):
4602–4609, 2000
79. Singh J, Kulkarni N, Kelloff G, Reddy BS: Modulation
of azoxymethane-induced mutational activation of ras pro-
tooncogenes by chemopreventive agents in colon carcino-
genesis. Carcinogenesis 15(7): 1317–1323, 1994
80. Shivapurkar N, Tang Z, Ferreira A, Nasim S, Garett C,
Alabaster O: Sequential analysis of K-ras mutations
in aberrant crypt foci and colonic tumors induced by
azoxymethane in Fischer-344 rats on high-risk diet.
Carcinogenesis 15(4): 775–778, 1994
81. Vivona AA, Shpitz B, Medline A, Bruce WR, Hay K,
Ward MA, Stern HS, Gallinger S: K-ras mutations
in aberrant crypt foci, adenomas and adenocarcino-
mas during azoxymethane-induced colon carcinogenesis.
Carcinogenesis 14(9): 1777–1781, 1993
82. Shivapurkar N, Belinsky SA, Wolf DC, Tang Z,
Alabaster O: Absence of p53 gene mutations in rat colon
carcinomas induced by azoxymethane. Cancer Lett 96(1):
63–70, 1995
83. Erdman SH, Wu HD, Hixson LJ, Ahnen DJ, Gerner EW:
Assessment of mutations in Ki-ras and p53 in colon cancers
from azoxymethane- and dimethylhydrazine-treated rats.
Mol Carcinog 19(2): 137–144, 1997
343
84. Koesters R, Hans MA, Benner A, Prosst R, Boehm J,
Gahlen J, Doeberitz MK: Predominant mutation of
codon 41 of the beta-catenin proto-oncogene in rat
colon tumors induced by 1,2-dimethylhydrazine using a
complete carcinogenic protocol. Carcinogenesis 22(11):
1885–1890, 2001
85. Wang QS, Papanikolau A, Sabourin CL, Rosenberg DW:
Altered expression of cyclin D1 and cyclin-dependent
kinase 4 in azoxymethane-induced mouse colon tumorige-
nesis. Carcinogenesis 19(11): 2001–2006, 1998
86. Luceri C, De Filippo C, Caderni G, Gambacciani L,
Salvatori M, Giannini A, Dolara P: Detection of somatic
DNA alterations in azoxymethane-induced F344 rat colon
tumors by random amplified polymorphic DNA analysis.
Carcinogenesis 21(9): 1753–1756, 2000
87. Luongo C, Gould KA, Su LK, et al.: Mapping of multiple
intestinal neoplasia (Min) to proximal chromosome 18 of
the mouse. Genomics 15: 3–8, 1993
88. Moser AR, Pitot HC, Dove WF: A dominant mutation that
predisposes to multiple intestinal neoplasia in the mouse.
Science 247: 322–324, 1990
89. Dietrich WF, Lander ES, Smith JS, et al.: Genetic iden-
tification of Mom-1, a major modifier locus affecting
Min-induced intestinal neoplasia in the mouse. Cell 75:
631–639, 1993
90. Oshima M, Dinchuk JE, Kargman SL, et al.: Suppression
of intestinal polyposis in Apc delta 716 knockout mice by
inhibition of cyclooxygenase 2 (COX-2). Cell 87: 803–809,
1996
91. Fodde R, Edelmann W, Yang K, et al.: A targeted chain-
termination mutation in the mouse Apc gene results in
multiple intestinal tumors. Proc Natl Acad Sci USA 91:
8969–8973, 1994
92. Smits R, Kartheuser A, Jagmohan-Changur S, et al.: Loss
of Apc and the entire chromosome 18 but absence of muta-
tions at the Ras and Tp53 genes in intestinal tumors from
Apc 1638N, a mouse model for Apc-driven carcinogene-
sis. Carcinogenesis 18: 321–327, 1997
93. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R,
Sigman CC: Progress in cancer chemoprevention: Perspec-
tives on agent selection and short-term clinical intervention
trials. Cancer Res 54(Suppl): 2015s–2024s, 1994
94. Lippman S, Lec J, Lotan R, et al.: Biomarkers as interme-
diate endpoints in chemoprevention trials. J Natl Cancer
Inst 82: 555, 1990
95. Einspahr JG, Alberts DS, Gapstur SM, et al.: Surrogate
end-point biomarkers as measures of colon cancer risk
and their use in cancer chemoprevention trials. Cancer
Epidemiol Biomarkers Prev 6: 37–48, 1997
96. O’Brien MJ, Winauer SJ, Zauber AG, et al.: The national
polyp study: Patient and polyp characteristics associated
with high-grade dysplasia in adenomas. Gastroenterology
98: 371–379, 1990
97. Hixson LJ, Fennerty MB, Sampliner RE, et al.: Two-year
incidence of colonic adenomas developing after tandem
colonoscopy. Am J Gastroenterol 89: 687–691, 1994
98. Kelloff GJ, Sigman CC, Johnson KM, Boone CW,
Greenwald P, Crowell JA, Hawk ET, Doody LA:
Perspectives on surrogate end points in the development
of drugs that reduce the risk of cancer. Cancer Epidemiol
Biomarkers Prev 9(2): 127–137, 2000
99. Fujii T, Rembacken BJ, Dixon MF, Yoshida S, Axon AT:
Flat adenomas in the United Kingdom: Are treatable can-
cers being missed? Endoscopy 30(5): 437–443, 1998
100. Kudo S, Kashida H, Tamura T, Kogure E, Imai Y,
Yamano H, et al.: Colonoscopic diagnosis and manage-
ment of nonpolypoid early colorectal cancer. World J Surg
24(9): 1081–1090, 2000
101. Muto T, Kamiya J, Sawada T, Konishi F, Sugihara K,
Kubota Y, et al.: Small ‘flat adenoma’ of the large bowel
with special reference to its clinicopathologic features. Dis
Colon Rectum 28(11): 847–851, 1985
102. Saitoh Y, Waxman I, West AB, Popnikolov NK, Gatalica Z,
Watari J, et al.: Prevalence and distinctive biologic features
of flat colorectal adenomas in a North American popula-
tion. Gastroenterology 120(7): 1657–1665, 2001
103. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P,
Jaramillo E, et al.: Genetic pathways in the evolution of
morphologically distinct colorectal neoplasms. Cancer Res
61(6): 2676–2683, 2001
104. Shiff SJ, Basil R: The role of cyclooxygenase inhbition in
the antineoplastic effects of nonsteroidal antiinflammatory
drugs (NSAIDs). J Exp Med 190(4): 445–450, 1999
105. Shureiqui I, Lippman SM: Lipooxygenase modulation to
reverse carcinogenesis. Cancer Res 61: 6307–6312, 2001
106. Pegg AE: Polyamine metabolism and its importance in neo-
plastic growth and as target for chemotherapy. Cancer Res
48: 759–774, 1988
107. Hixson LJ, Garewal HS, McGee DL, Sloan D,
Fennerty MB, Sampliner RE, Gener EW: Ornithine decar-
boxylase and polyamines in colorectal neoplasia and
mucosa. Cancer Epidemiol Biomarkers Prev 2: 369–374,
1993
108. Goodman G: The clinical evaluation of chemoprevention
agents: Defining and contrasting phase I, II, III objectives.
Cancer Res 52: 2752–2758, 1992
109. Einspahr J, Alberts D, Xie T, et al.: Comparison of prolif-
erating cell nuclear antigen versus the more standard mea-
sures of rectal mucosal proliferation rates in subjects with a
history of colorectal cancer and normal age-matched con-
trols. Cancer Epidemiol Biomarkers Prev 4: 359–366, 1995
110. Boland CR, Montgomery CK, Kim YS: Alterations in
human colonic mucin occurring with cellular differenti-
ation and malignant transformation. Proc Natl Acad Sci
USA 79: 2051–2055, 1988
111. Sam JS, Lynch HT, Burt RW, et al.: Abnormalities of lectin
histochemistry in familial polyposis coli and hereditary
nonpolyposis colorectal cancer. Cancer 66: 502–508, 1990
112. Hall PA, Coates PJ, Ansari B, Hopwood D: Regulation of
cell number in the mammalian gastrointestinal tract: The
importance of apoptosis. J Cell Sci 107: 3569–3577, 1994
113. Bedi A, Pasricha PJ, Akhtar AJ, et al.: Inhibition of apop-
tosis during development of colorectal cancer. Cancer Res
55: 1811–1816, 1995
114. Piazza G, Rahm A, Krutzsch M, et al.: Antineoplastic drugs
sulindac sulfide and sulfone inhibit cell growth by inducing
apoptosis. Cancer Res 55: 3110–3116, 1995
344
115. Barnes C, Cameron I, Hardman W, Lee M: Non-steroidal
anti-inflammatory drug effect on crypt cell proliferation
and apoptosis during initiation of rat colon carcinogenesis.
Br J Cancer 77: 573–580, 1998
116. Stoner GD, Budd GT, Ganapathu R, DeYoung B,
Kresty LA, Nitert M, Fryer B, Church JM, Provencher K,
Pamucku R, Piazza G, Hawk E, Kelloff G, Elson P,
van Stolk RU: Sulindac sulfone induced regression of rec-
tal polyps in patients with familial adenomatous polyposis.
Adv Exp Med Biol 470: 45–53, 1999
117. DuBois RN, Shao J, Tsujii M, et al.: G1 delay in cells over-
expressing prostaglandin endoperoxide synthase-2. Cancer
Res 56: 733–737, 1996
118. Shureiqui I, Lippman SM: Lipoxygenase modulation to
reverse carcinogenesis. Cancer Res 61: 6307–6312, 2001
119. Narumiya S, Fitzgerald GA: Genetic and pharmacologi-
cal analysis of prostanoid receptor function. J Clin Invest
108(1): 25–30, 2001
120. Watanabe K, et al.: Role of prostaglandin E receptor
subtype EP1 in colon carcinogenesis. Cancer Res 59:
5093–5096, 1999
121. Crist K, Wang Y, Lubet R, et al.: P 53 accumulation and
K-ras mutations as surrogate endpoint biomarkers (SEBs)
for chemoprevention in a rat colon tumor model. Proc Am
Assoc Cancer Res 36: A591, 1995
122. Singh J, Kelloff G, Reddy BS: Intermediate biomarkers of
colon cancer: Modulation of expression of ras oncogene
by chemopreventive agents during azoxymethane induced
colon carcinogenesis. Carcinogenesis 14: 699–704, 1993
123. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP:
Alterations in DNA methylation: A fundamental aspect of
neoplasia. Adv Cancer Res 72: 141–196, 1998
124. Bird AP: CpG-rich islands and the function of DNA methy-
lation. Nature 321: 206–213, 1986
125. Bird A: The essentials of NA methylation. Cell 70: 5–8,
1992
126. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM,
Dryja TP: Allele-specific hypermethylation of the
retinoblastoma tumor-suppressor gene. Am J Hum Genet
48: 880–888, 1991
127. Bird AP, Wolffe AP: Methylation-induced repression:
Belts, braces and chromatin. Cell 99: 451–454, 1999
128. Jones PL, Wolffe AP: Relationships between chromatin
organization an DNA methylation in determining gene
expression. Semin Cancer Biol 9: 339–347, 1999
129. Herman JG, Merlo A, Mao L, et al.: Inactivation of the
CDKN2/p16/MTS1 gene is frequently associated with
aberrant DNA methylation in all common human cancers.
Cancer Res 55: 4525–4530, 1995
130. Herman JG, Umar A, Polyak K, et al.: Incidence and func-
tional consequences of hMLH1 promoter hypermethyla-
tion in colorectal carcinoma. Proc Natl Acad Sci USA 95:
6870–6875, 1998
131. Esteller M, Sparks A, Toyota M, et al.: Analysis of ade-
nomatous polyposis coli promoter hypermethylation in
human cancer. Cancer Res 60: 4366–4371, 2000
132. Jubb AM, Bell SM, Quirke P: Methylation and colorectal
cancer. J Pathol 195: 111–134, 2001
133. Issa JP: CpG-island methylation in aging and cancer. Curr
Top Microbiol Immunol 249: 101–118, 2000
134. Logan RFA, Little J, Hawtin PG, Hardcastle JD: Effect of
aspirin and non-steroidal anti-inflammatory drugs on col-
orectal adenomas: Case-control study of subjects partic-
ipating in the Nottingham faecal occult blood screening
programme. BMJ 307: 285–289, 1993
135. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA,
Ascherio A, Willett WC: Aspirin use and the risk for col-
orectal cancer and adenoma in male health professionals.
Ann Intern Med 121: 241–246, 1994
136. Kune G, Kune S, Watson L: Colorectal cancer risk, chronic
illnesses, operations and medications: Case control results
from the Melbourne Colorectal Cancer Study. Cancer Res
48: 4399–4404, 1988
137. Thun MJ, Namboodiri MM, Heath CW Jr.: Aspirin use
and reduced risk of fatal colon cancer. N Engl J Med 328:
1593–1596, 1991
138. Paganini-Hill A, Hsu G, Ross RK, Henderson BE: Aspirin
use and incidence of large bowel cancer in a California
retirement community. J Natl Cancer Inst 83: 1182–1183,
1991
139. Moorghen M, Ince P, Finney KJ, Suhnter JP, Watson AJ,
Appleton DR: The effect of sulindac on colonic tumour
formation in dimethylhydrazine-treated mice. Acta Histo-
chemica 34(Suppl): 195–199, 1990
140. Pollard M, Luckert PH: Treatment of chemically-induced
intestinal cancer with indomethacin. Proc Soc Exp Biol
Med 167: 161–164, 1981
141. Pollard M, Luckert PH: Effect of indomethacin on intesti-
nal tumor induced in rats by the acetate derivative of
dimethylnitrosamine. Science 214: 558–559, 1981
142. Pollard M, Luckert PH, Schmidt MA: The suppressive
effect of piroxicam on autochronous intestinal tumors in
the rat. Cancer Lett 21: 57–61, 1983
143. Reddy BS, Maruyama H, Kelloff G: Dose-related inhibi-
tion of colon carcinogenesis by dietary piroxicam, a non-
steriodal anti-inflammatory drug, during different stages of
rat colon tumor development. Cancer Res 47: 5340–5346,
1987
144. Baron J, Tosteson T, Wargovich M, Sandler R, Mandel J,
Bond J, et al.: Calcium supplementation and rectal mucosal
proliferation: A randomized controlled trial. J Natl Cancer
Inst 87: 1303–1307, 1995
145. Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory
effect of aspirin on azoxymethane-induced colon carcino-
genesis in F344 rats. Carcinogenesis 14: 1493–1497, 1993
146. Kawamori T, Rao C, Seibert K, Reddy B: Chemopreventive
effect of celecoxib, a specific cyclooxygenase-2 inhibitor
on colon carcinogenesis. Cancer Res 58: 409–412, 1998
147. Oshima M, Dinchuk J, Kargman S, Oshima H, Hancock B,
Kwong E, et al.: Suppression of intestinal polyposis in Apc
delta 716 knockout mice by inhibition of cyclooxygenase
2 (COX-2). Cell 87: 803–809, 1996
148. Laboyle D, Fischer D, Vielh P, et al.: Sulindac causes
regression of rectal polyps in familial adenomatous poly-
posis. Gastroenterology 101: 635–639, 1991
149. Nugent KP, Farmer KCR, Spigelman AD, Williams CB,
Phillips RKS: Randomized controlled trial of the effect of
345
sulindac on duodenal and rectal polyposis and cell prolifer-
ation in patients with familial adenomatous polyposis. Br J
Surg 80: 1618–1619, 1993
150. Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment
of colonic and rectal adenomas with sulindac in familial
adenomatous polyposis. N Engl J Med 328: 1313–1316,
1993
151. Steinbach G, Lynch PM, Phillips RKS, et al.: The effect of
celecoxib a cyclooxygenase-2 inhibitor in familial adeno-
matous polyposis. N Engl J Med 342: 1946–1952, 2000
152. Keller JJ, Offerhaus GJ, Polak M, et al.: Rectal epithe-
lial apoptosis in familial adenomatous polyposis patients
treated with sulindac. Gut 45: 822–828, 1999
153. Spagnesi M, Tonelli F, Dolara P, et al.: Rectal proliferation
and polyp recurrence in patients with familial adenomatous
polyposis after sulindac treatment. Gastroenterology 106:
362–366, 1994
154. Block G, Patterson B, Subar A: Fruit, vegetables and cancer
prevention: A review of the epidemiological evidence. Nutr
Cancer 18(1): 1–29, 1992
155. Leclercq C, Valsta LM, Turrini A: Food composition
issues – implications for the development of food-based
dietary guidelines. Public Health Nutr 4(2B): 677–682,
2001
156. Bostick RM, Potter JD, Sellers TA, McKenzie DR,
Kushi LH, Folsom AR: Relation of calcium, vitamin D,
and dairy food intake to incidence of colon cancer among
older women. The Iowa Women’s Health Study. Am J Epi-
demiol 137: 1302–1317, 1993
157. Tseng M, Murray SC, Kuper LL, Sandler RS: Micronutri-
ents and the risk of colorectal adenomas. Am J Epidemiol
144(11): 1026–1027, 1996
158. Kampman E, Goldbohm RA, van den Brandt PA,
Van’t Veer P: Fermented dairy products, calcium and col-
orectal cancer in the Netherlands Cohort Study. Cancer Res
54(12): 3186–3190, 1994
159. Little J, Logan RF, Hawtin PG, Hardcastle JD, Turner ID:
Colorectal adenomas and diet: A case-control study of sub-
jects participating in the Nottingham faecal occult blood
screening programme. Br J Cancer 67: 177–184, 1993
160. Neugut AI, Horvath K, Whelan RL, Terry MB,
Garbowski GC, Bertram A, Forde KA, Treat MR, Waye J:
The effect of calcium and vitamin supplements on the inci-
dence and recurrence of colorectal adenomatous polyps.
Cancer 78(4): 723–728, 1996
161. Bergma-Kadijk JA, van’t Veer P, Kampman E, Burema J:
Calcium does not protect against colorectal neoplasia.
Epidemiology 7(6): 590–597, 1996
162. Bostick RM, Potter JD, Fosdick L, et al.: Calcium and col-
orectal epithelial cell proliferation. A preliminary random-
ized, double-blind, placebo-controlled clinical trial. J Natl
Cancer Inst 85: 132–141, 1993
163. Newmark HL, Wargovich MJ, Bruce WR: Colon cancer
and dietary fat, phosphate, and calcium: A hypothesis.
J Natl Cancer Inst 72: 1323–1325, 1984
164. Pence BC: Role of calcium in colon cancer prevention:
Experimental and clinical studies. Mutat Res 290: 87–95,
1993
165. Lipkin M, Newmark H: Effect of added dietary calcium
on colonic epithelial-cell proliferation in subjects at high
risk for familial colonic cancer. N Engl J Med 313(22):
1381–1384, 1985
166. Wargovich MJ, Isbell G, Shabot M, Winn R, Lanza F,
Hochman L, Larson E, Lynch P, Roubein L, Levin B:
Calcium supplementation decreases rectal epithelial
cell proliferation in subjects with sporadic adenoma.
Gastroenterology 103(6): 1994–1995, 1992
167. Cats A, Kleibeuker JH, van der Meer R, Kuipers F,
Sluiter WJ, Hardonk MJ, Oremus ET, Mulder NH,
de Vries EG: Randomized, double-blinded, placebo-
controlled intervention study with supplemental calcium
in families with hereditary nonpolyposis colorectal cancer.
J Natl Cancer Inst 87: 598–603, 1995
168. Stern HS, Gregoire RC, Kashtan H, Stadler J, Bruce RW:
Long-term effects of dietary calcium on risk markers for
colon cancer in patients with familial polyposis. Surgery
108(3): 528–533, 1990
169. Baron JA, Tosteson TD, Wargovich MJ, Sandler R,
Mandel J, Bond J, Haile R, Summers R, van Stolk R,
Rothstein R: Calcium supplementation and rectal mucosal
proliferation: A randomized controlled trial. J Natl Cancer
Inst 87(17): 1303–1307, 1995
170. Lupton JR, Steibach G, Chang WC, O’brien BC, Wiese S,
Stoltzfus CL, Glober GA, Wargovich MJ, McPherson RS,
Winn RJ: Calcium supplementation modifies the relative
amounts of bile acids in bile and affects key aspects of
human colon physiology. J Nutr 126(5): 1421–1428, 1996
171. Alberts DS, Ritenbaugh C, Story JA, Aickin M,
Rees-McGee S, Buller MK, Atwood J, Phelps J,
Ramanujam PS, Bellapravalu S, Patel J, Bextinger L,
Clark L: Randomized, double-blinded, placebo-controlled
study of effect of wheat bran fiber and calcium on fecal bile
acids in patients with resected adenomatous colon polyps.
J Natl Cancer Inst 88(2): 81–92, 1996
172. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW,
Sandler RS, Rothstein R, Summers RW, Snover DC,
Beck GJ, Frankl H, Pearson L, Bond JH, Greenberg ER:
Calcium supplements and colorectal adenomas. Ann NY
Acad Sci 889: 138–145, 1999
173. Burkitt DP: Epidemiology of cancer of the colon and rec-
tum. Cancer 28: 3–13, 1971
174. Reddy BS, Hedges AR, Laaskso K, et al.: Metabolic epi-
demiology of large bowel cancer: Fecal bulk and con-
stituents of high-risk North American and low-risk Finnish
population. Cancer 42: 2832–2838, 1978
175. Hill MJ: Dietary fibre and human cancer: Epidemiological
data. Adv Exp Med Biol 427: 27–34, 1997
176. Lupton JR: Is fiber protective against colon cancer? Where
the research is leading us. Nutrition 16(7–8): 558–561,
2000
177. Eastwood MA, Hamilton D: Studies on the absorption of
bile salts to non-adsorbed components of diet. Biochim
Biophys Acta 152(1): 165–173, 1968
178. Kritchevsky D: Epidemiology of fibre, resistant starch and
colorectal cancer. Eur J Cancer Prev 4: 345–352, 1995
179. D’Argenio G, Cosenza V, Cave MD, et al.: Butyrate pro-
duction from dietary fibre and protection against large
346
bowel cancer in a rat model. Gastroenterology 110:
1727–1734, 1996
180. Hill MJ: Cereals, cereal fibre and colorectal cancer risk:
A review of the epidemiological literature. Eur J Cancer
Prev 7(Suppl 2): S5–S10, 1998
181. Alberts DS, Martinez ME, Roe DJ, et al.: Lack of effect
of a high-fiber cereal supplement on the recurrence of col-
orectal adenomas. N Engl J Med 342: 1156–1162, 2000
182. Schatzkin A, Lanza E, Corle D, et al.: Lack of effect of
a low-fat, high-fiber diet on the recurrence of colorectal
adenomas. N Engl J Med 342: 1149–1155, 2000
183. Glynn SA, Albanes D, Pietinen P, Brown CC, Rautalahti M,
Tangrea JA, Gunter EW, Barrett MJ, Virtamo J, Taylor PR:
Colorectal cancer and folate status: A nested case-control
study among male smokers. Cancer Epidemiol Biomarkers
Prev 5: 487–494, 1996
184. White E, Shannon JS, Patterson RE: Relationship between
vitamin and calcium supplement use and colon cancer.
Cancer Epidemiol Biomarkers Prev 6(10): 769–774, 1997
185. Su LJ, Arab L: Eating patterns and risk of colon cancer.
Am J Epidemiol 148(1): 4–16, 1998
186. Freudeheim JL, Graham S, Marshall JR, Haugey BP,
Cholewinski S, Wilkinson G: Folate intake and carcino-
genesis of the colon and rectum. Int J Epidemiol 20(2):
368–374, 1991
187. Lashner BA, Heidenreich PA, Su GL, Kane SV,
Hanauer SB: Gastroenterology 97(2): 255–259, 1989
188. Lashner BA: Red blood cell folate is associated with the
development of dysplasia and cancer in ulcerative colitis.
J Cancer Res Clin Oncol 119(9): 549–554, 1993
189. Ma J, Stampfer NJ, Giovanucci E, et al.: Methylenetetrahy-
drofolate reductase polymorphism, detary interactions, and
risk of colorectal cancer. Cancer Res 57: 1098–1102, 1997
190. Chen J, Giovanucci E, Hankinson SE, et al.: A prospective
study of methylenetetrahydrofolate reductase and methio-
nine synthase gene polymorphisms, and risk of colorectal
adenoma. Carcinogenesis 19: 2129–2132, 1998
191. Giovannucci E, Stampfer MJ, Colditz GA, et al.: Folate,
methionine, and alcohol intake and risk of colorectal
adenoma. J Natl Cancer Inst 85: 875–883, 1993
192. Cravo M, Fidalgo P, Pereira A, et al.: DNA methylation
as an intermediate biomarker in colorectal cancer: Modu-
lation by folic acid supplementation. Eur J Cancer Prev 3:
473–479, 1994
193. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ,
Colditz GA, Willett WC: Alcohol, low-methionine – low
folate diets, and risk of colon cancer in men. J Natl Cancer
Inst 86(4): 265–273, 1995
194. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ,
Fuchs C, Rosner BA, Speizer FE, Willett WC: Multivita-
min use, folate and colon cancer in women in the Nurses’
Health Study. Ann Intern Med 129(7): 517–524, 1998
195. Kim YI, Baik HW, Fawaz K, Knox T, Lee YM, Norton R,
Libby E, Mason JB: Effects of folate supplementation
on two provisional molecular markers of colon cancer:
A prospective randomized trial. Am J Gastroenterol 96(1):
184–195, 2001
196. Reddy B, Rivenson A, El-Bayoumy K, Upadhyaya P,
Pittman B, Rao C: Chemoprevention of colon cancer by
organoselenium compounds and impact of high- and low-
fat diets. J Natl Cancer Inst 89: 506–512, 1997
197. Reddy B, Xan C, Samaha H, Lubet R, Steele V, Kelloff G,
Rao S: Chemoprevention of colon carcinogenesis by
dietary perillyl alcohol. Cancer Res 57: 420–425, 1997
198. Tanaka T, Kawata K, Kakumoto M, Hara A, Murakami A,
Kuki W, et al.: Citrus auraptene exerts dose-dependent
chemopreventive activity in rat large bowel tumorigenesis:
The inhibition correlates with suppression of cell prolifer-
ation and lipid peroxidation and with induction of Phase II
drug metabolizing enzymes. Cancer Res 58: 2550–2556,
1998
199. Tanaka T, Kawabata K, Kakumoto M, Makita H,
Matsunaga K, Mori H, et al.: Chemoprevention of
azoxymethane-induced rat colon carcinogenesis by a xan-
thine oxidase inhibitor, 1′-acetoxychavicol acetate. Jpn J
Cancer Res 88: 821–830, 1997
200. Tanaka T, Makita H, Satoh K, et al.: Chemoprevention
of azoxymethane-induced rat colon carcinogenesis by the
naturally-occurring flavonoids, diosmin and hesperidin.
Carcinogenesis 18: 957–965, 1997
201. Rao CV, Rivenson A, Simi, B, Reddy BS: Chemopreven-
tion of colon carcinogenesis by dietary curcumin, a natu-
rally occurring plant phenolic compound. Cancer Res 55:
259–266, 1995
202. Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR,
Conney AH: Inhibitory effects of dietary curcumin on
forestomach, duodenal and colon carcinogenesis in mice.
Cancer Res 54: 5841–5847, 1994
203. Hanif R, Qiao L, Shiff S, Rigas B: Curcumin, a natural
plant phenolic food additive inhibits cell proliferation and
induces cell cycle changes in colon adenocarcinoma cell
lines by a prostaglandin-independent pathway. J Lab Clin
Med 130: 576–584, 1997
204. Cheng AL, Lin JK, Hsu MM, Shen TS, Ko JY, Lin JT,
Wu MS, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA,
Lai MK, Pu YS, Pan MH, Wang UJ, Tsai CC, Hsieh CY:
Phase I chemoprevention clinical trial of curcumin. Proc
Am Soc Clin Oncol 17: 558a, 1998
205. Grodstein F, Newcomb PA, Stampler MJ: Postmenopausal
hormone therapy and the risk of colorectal cancer: A review
and meta-analysis. Am J Med 106(5): 574–582, 1999
206. Wysowski DK, Golden L, Burke L: Use of menopausal
estrogens and medroxyprogesterone in the United States,
1982–1992. Obstet Gynecol 85: 6–10, 1995
207. Fernandez E, La Vecchia C, Braga C, et al.: Hormone
replacement therapy and risk fo colon and rectal cancer.
Cancer Epidemiol Biomarkers Prev 7: 329–333, 1998
208. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr.:
Estrogen replacement therapy and risk of fatal colon cancer
in a prospective cohort of postmenopausal women. J Natl
Cancer Inst 87: 517–523, 1995
209. Grodstein F, Platz EA, Giovannucci E, Colditz GA,
Kantzky M, Fuchs C, Stampfer MJ: Postmenopausal hor-
mone use and risk of colorectal cancer and adenoma. Ann
Intern Med 128: 705–712, 1998
210. McMichael AJ, Potter JD: Reproduction, endogenous and
exogenous sex hormones, and colon cancer: A review and
hypothesis. J Natl Cancer Inst 65: 1201–1207, 1980
347
211. Ma J, Pollak MN, Giovannucci E, et al.: Prospec-
tive study of colorectal cancer risk in men and plasma
levels of insulin-like growth factor (IGF)-I and IGF-
binding protein-3. J Natl Cancer Inst 91: 620–625,
1999
212. Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN,
Anderson K, Schaffer D, Samowitz WS: Estrogens reduce
and withdrawal of estrogens increase risk of microsatel-
lite instability-positive colon cancer. Cancer Res 61(1):
126–130, 2001
213. Arai N, Strom A, Rafter JJ, Gustafsson JA: Estrogen recep-
tor beta mRNA in colon cancer cells: Growth effects of
estrogen and genistein. Biochem Biophys Res Com 270(2):
425–431, 2000
214. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML:
Functional estrogen receptor beta in colon cancer
cells. Biochem Biophys Res Com 261(2): 521–527,
1999
215. Alford TC, Do HM, Geelhoed GW, Tsangaris NT,
Lippman ME: Steroid hormone receptors in human colon
cancers. Cancer 43(3): 980–984, 1979
216. Lointier P, Wildrick DM, Boman BM: The effects of steroid
hormones on a human colon cancer cell line in vitro.
Anticancer Res 12(4): 1327–1330, 1992
217. Ziv Y, Gupta MK, Milsom JW, Vladisavljevic A, Kitago K,
Fazio VW: The effect of tamoxifen on established human
colorectal cancer cell lines in vitro. Anticancer Res 16(6B):
3767–3771, 1996
218. Picariello L, Fiorelli G, Brandi ML, Galli G,
Malentacchi C, Montali E, Bigozzi U, Ficari F, Tonelli F:
In vitro bioeffects of the antiestrogen LY117018 on
desmoid tumor and colon cancer cells. Anticancer Res
17(3C): 2099–2104, 1997
219. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T:
Tamoxifen and gonadal steroids inhibit colon cancer
growth in association with inhibition of thymidylate syn-
thase, survivin and telomerase expression through estrogen
receptor beta mediated system. Cancer Lett 161(1): 63–71,
2000
220. Ranelletti FO, Ricci R, Larocca LM, Maggiano N,
Capelli A, Scambia G, Benedetti-Panici P, Mancuso S,
Rumi C, Piantelli M: Growth-inhibitory effect of quercetin
and presence of type-II estrogen-binding sites in human
colon-cancer cell lines and primary colorectal tumors.
Int J Cancer 50(3): 486–492, 1992
221. Ziv Y, Fazio VW, Kitago K, Gupta MK, Sawady J,
Nishioka K: Effect of tamoxifen on 1,2-dimethyl-
hydrazine-HCl-induced colon carcinogenesis in rats. Anti-
cancer Res 17(2A): 803–810, 1997
222. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B:
The protective effect of estrogen against chemical induced
murine colon carcinogenesis is associated with decreased
CpG island methylation and increased mRNA and protein
expression of the colonic vitamin D receptor. Oncol Res
11(6): 255–264, 1999
223. Gamet I, Cazenave Y, Trocheris V, et al.: Involvement of
ornithine decarboxylase in the control of proliferation of
the HT29 human colon cancer cell line. Int J Cancer 47:
633–638, 1991
224. Luk GD, Baylin SB: Ornithine decarboxylase as a biologic
marker in familial colonic polyposis. N Engl J Med 311:
80–83, 1984
225. Thompson H, Ronan A: Effect of D,L-2-
difluoromethylornithine and endocrine manipulation of
the induction of mammary carcinogenesis by 1-methyl-1-
nitrosurea. Carcinogenesis 7: 2003–2006, 1986
226. Boyle JO, Meyskens FL Jr., Garewal HS, Gerner EW:
Polyamine contents in rectal and buccal mucosa in humans
treated with oral difluoromethylornithine. Cancer Epi-
demiol Biomarkers Prev 1: 131–135, 1992
227. Love R, Carbone P, Verma A, et al.: Random-
ized phase I chemoprevention dose seeking study of
α-difluoromethylornithine. J Natl Cancer Inst 85: 732–737,
1993
228. Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K,
Pomplun M, Verma AK: A randomized, placebo-controlled
trial of low-dose alpha-difluoromethylornithine in individ-
uals at risk for colorectal cancer. Cancer Epidemiol Bio
Prev 7(11): 989–992, 1998
229. Meyskens FL, Emerson SS, Pelot D, Meshkinpour H,
Shassetz LR, Einspaar J, et al.: Dose de-escalation chemo-
prevention trial of α-difluoromethylornithine in patients
with colon polyps. J Natl Cancer Inst 85: 732–736, 1994
230. Meyskens FL, Gerner EW, Emerson S, Pelot D,
Durbin T, Doyle K, Lagerberg W: Effects of
α-difluoromethylornithine on rectal mucosal levels of
polyamines in a randomized, double-blinded trial for colon
cancer prevention. J Natl Cancer Inst 90(16): 1212–1218
231. O’Dwyer ME, Druker BJ: STI571: An inhibitor of the
BCR-ABL tyrosine kinase for the treatment of chronic
myelogenous leukaemia. Lancer Oncol 1: 207–211, 2000
232. Meyskens F: Principles of human chemoprevention.
Hematol Oncol Clin North Am 12(5): 1–7, 1998
233. Coffey R, Hawkey C, Damstrup L, Graves-Deal R,
Daniel V, Dempsey P, et al.: Epidermal growth fac-
tor receptor activation induces nuclear targeting of
cyclooxygenase-2, basolateral release of prostaglandins,
and mitogenetis in polarizing colon cancer cells. Proc Natl
Acad Sci USA 94: 657–662, 1997
234. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM,
DuBois RN, et al.: Transforming growth factor-beta1
enhances Ha-ras-induced expression of cyclooxygenase-2
in intestinal epithelial cells via stabilization of mRNA.
J Biol Chem 275(9): 6628–6635, 2000
235. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN,
Beauchamp RD: Cyclooxygenase-2 induction and trans-
forming growth factor beta growth inhibition in rat intesti-
nal epithelial cells. Cell Growth Differ 8(4): 463–470, 1997
236. Torrance CJ, Jackson PE, Montgomery E, Kunzler KW,
Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM:
Combinatorial chemoprevention of intestinal neoplasia.
Nat Med 6(9): 1024–1028, 2000
237. Gupta RS, DuBois RN: Combinations for cancer
prevention. Nat Med 6(9): 974–975, 2000
238. Jacoby RF, Cole CE, Tetsch K, Newton MA, Kelloff G,
Hawk ET, Lubet RA: Chemoprevention efficacy of com-
bined piroxicam and difluoromethylornithine treatment of
348
Apc mutant Min mouse adenomas, and selective tox-
icity against Apc mutant embryos. Cancer Res 60(7):
1864–1870, 2000
239. Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA,
Pomplun M, Tutsch KD: Phase I chemoprevention study
of piroxicam and alpha-difluoromethylornithine. Cancer
Epidemiol Biomarkers Prev 7(10): 907–912, 1998
240. Harris G, Gupta A, Nines R, Kresty L, Habib S, Frankel W,
et al.: The effects of lyophilized black raspberries on
azoxymethane-induced colon cancer and 8-hydroxy-2′-
deoxyguanosine levels in the Fischer 344 rat. Nutr Cancer
40(2): 125–133, 2001
241. Li H, Kramer P, Lubet R, Steele V, Kelloff G, Pereira M:
Effects of calcium on azoxymethane-induced aberrant
crypt foci and cell proliferation in the colon of rats. Cancer
Lett 124: 39–46, 1998
242. Deschner EE, Cohen BI, Raicht RF: The kinetics of the
protective effect of beta-sitosterol against MNU-induced
colonic neoplasia. J Cancer Res Clin Oncol 103(1): 49–54,
1982
243. Rao C, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy B:
Chemoprevention of colon carcinogenesis by dietary
administration of piroxicam, a-difluoromethylornithine,
16-a-fluoro-5-androsten-17-one, and ellagic acid individ-
ually and in combination. Cancer Res 51: 4528–4534,
1991
Address for offprints: David Gustin, MD. The University
of Chicago, Section of Hematology/Oncology, 5841 South
Maryland Ave, Room P312, MC 2115, Chicago, IL, 60637-1470;
e-mail: dgustin@medicine.bsd.uchicago.edu
